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1. Summary
Background: CD8^ T cells are critical not only for the termination of acute viral 
infections but also for the long-term control of viruses capable to establish persistent 
infection such as Human Immunodeficiency Virus (HIV), Hepatitis B and C virus (HBV 
and HCV), Epstein Barr Virus (EBV) and Cytomegalovirus (CMV). The level of viral 
persistence (or antigen load) has an important impact on the magnitude and the quality of 
virus-specific T cells and vice versa. Usually, high antigen load during a prolonged 
period of time has a damaging influence on the fimctionality of antiviral T cell 
responses. However, it is less clear whether low level antigen persistence is beneficial or 
detrimental for the maintenance of virus specific T cells and ultimately for protective T 
cell memory. This has obvious implications for vaccine design.
Hypothesis: I speculated that antigen persistence at a low level is beneficial for the long­
term maintenance of virus specific CD8^ T cells and for their protective capacity against 
challenge infections.
Methods: Mice were infected with mouse cytomegalovirus (MCMV), which leads to a 
low level persistent or latent infection with the potential for viral reactivation. To 
compare the long-term dynamics of virus specific CD 8  ^T cells after persistent (MCMV) 
or transient infections [Vaccinia virus (W ), Influenza A virus (Influenza)], I used 
recombinant MCMV expressing T cell epitopes derived from heterologous viruses. 
Thereafter, I longitudinally characterized the magnitude, the phenotype and the
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functionality of CD8^ T cells specific for native and recombinant epitopes in detail and 
tested their long-term protective capacity against viral challenge.
Results: This longitudinal analysis of the native MCMV-specific CD8^ T cell response 
revealed a most unusual pattern of T cell dynamics: after initial expansion and limited 
contraction MCMV-specific memory CD8^ T cells steadily accumulated over time, with 
20% of all CD8^ T cells being specific for a single MCMV-derived T cell epitope at one 
year after infection. Accumulation of effector memory T cells was seen in all organs 
tested and was accompanied by a gradual restriction in T cell receptor Vp chain usage 
over time. The pattern of accumulation, which I have termed ‘memory inflation’, was 
observed only in two out of five epitopes tested. Responses against other tested epitopes 
followed more ‘classical’ dynamics with initial expansion and contraction to stable 
memory T cell levels.
Challenge with recombinant W  more than 6 months after MCMV-infection provoked 
vigorous expansion of these ‘inflated’ effector memory T cells, which mediated 
immediate protection against challenge. Accumulation of effector memory T cells was 
also seen after infection with recombinant MCMV and long-term protective immunity, 
based on recombinant T cell epitopes, was maintained more efficiently than after 
transient infection with non-persisting viruses, which expressed identical epitopes.
Conclusions: My results have two major implications: 1) ‘Memory inflation’ is a 
previously ururecognised pattern of an antiviral T cell response, which is most likely 
driven by continuous or repetitive antigen encounter during latent or low-level persistent 
MCMV-infection. Recent cross-sectional studies in humans suggest that similar virus-
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host interactions might exist for human viral infections particularly with CMV and EBV. 
2) Effector memory T cells accumulating during low-level persistent infection provide 
efficient long-term protective T cell immunity without the need for boosting. These 
results demonstrate that low-level antigen persistence is beneficial for protective T cell 
memory and they provide the first ‘proof-of-principle’ evidence to encourage further 
exploration of persistent ‘self-boosting’ vectors for the development of successful T cell 
based vaccines.
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2. General Introduction
2.1. Persistent infections
Persistent infections of humans are an enormous problem both for the affected individual 
and for human society in general. Infection with human immunodeficiency virus (HIV) 
and subsequent acquired immune-deficiency syndrome (AIDS) has become the most 
prominent cause of death for adults in sub-Saharan Africa and infection rates are still 
rising, reaching up to 40% of working age people in some areas. By December 2003 
WHO estimated that about 40 Mio people are currently infected with this persistent virus 
and that per day 14’000 new infections occur worldwide (1).
Furthermore, other persistent human pathogens including viruses, bacteria and parasites, 
which have plagued the human race for much longer than HTV are far from under 
control. Tuberculosis and leprosy are the most prominent bacterial examples, viruses 
include hepatitis B and C virus (HBV and HCV) and all of the herpesviruses. Parasitic 
infections like trypanosomiasis, some forms of malaria and toxoplasmosis can establish 
persistent infection as well. However, many of these infections can be controlled by the 
host’s immune system for a very long time and sometimes for life without overt disease. 
Some of these organisms have reached a remarkable state of more or less peaceful 
coexistence with their host during evolution. Since seroprevalence for these infections 
can reach up to 95%, coinfection and superinfection with HTV is now frequently 
encountered. With increasing immunosuppression during the development of AIDS, 
immune control over these pathogens is lost leading to disease and death. Reactivation 
of persistent infections poses an additional problem in modem medicine as a
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complication of therapeutical immuno-suppression during organ transplantation and 
treatment of cancer, leukaemia and autoimmune disease.
Therefore, our understanding of persistent infections and of the factors influencing their 
control within individuals and within the susceptible population is highly relevant for 
their prevention and treatment. Understanding the interactions of these infectious 
organisms with the immune system of the host is central for the rational development of 
immune based prevention (prophylactic vaccines) and treatment strategies (therapeutic 
vaccines and immunotherapy).
The direct manipulation of an infectious disease and of the ensuing immune response in 
humans is often not possible. Moreover, in vitro studies cannot imitate the complexities 
of two biological systems in a dynamic interaction, i.e. virus infection, dissemination and 
establishment of latency versus a complex immune response with various effector 
mechanisms. Particularly the geographical and sequential variety and complexity of 
events, which take place during the course of an infection of a vertebrate host with a 
pathogen, are beyond the scope of in vitro systems. Therefore, animal models have been 
used for decades to study infections and their consequences for the host. However, 
whether basic principles established in animal models apply for infections in humans has 
to be tested individually before general conclusions can be drawn.
Mice have been the study animal species of choice for immunology during the last 50 
years. Thus, we know more about mouse immunology than of any other species except 
humans. However, only few mouse models have been developed for the study of 
persistent viral infections, but they have contributed tremendously to our understanding 
of successful and failing immune control of persistent infections.
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The following studies of mouse cytomegalovirus (MCMV) infection were undertaken to 
learn more about the immune response against persistent viruses in general and to further 
characterize a well established animal model of an important human pathogen with 
current immunological techniques.
2.2. Human and mouse cytomegalovirus
Cytomegaloviruses (CMV) belong to the family of p-herpesviruses. They share many 
biologic features with other herpesviruses including virion and genome structure, and the 
ability to establish persistent and latent infection. Since they have coevolved with their 
hosts for millions of years, they are highly species specific and many different animal 
species have their ‘private’ CMV. Infection across species barriers is usually not possible 
(2).
2.2.1. Epidemiology and clinical symptoms
CMVs are evolutionary very successful and they are highly adapted to their respective 
host. In humans, 60-90% of the adult population are healthy, seropositive carriers of 
human (H) CMV. Most people acquire infection before puberty: up to 2% are infected 
during gestation, another 8-60% during the first 6 months of life (during birth, by breast 
feeding) and about 20-80% during the next five years mainly by close contact to infected 
children (nurseries). Sexual transmission represents another major route of infection in 
adulthood (3).
Primary HCMV-infection in immunocompetent individuals is usually clinically silent. 
Rarely, a self-limiting mononucleosis-like syndrome with fever, myalgias, splenomegaly 
and abnormal liver function tests can be attributed to acute HCMV-infection. More
12
MCMV as a model for persistent viral infection PhD-Thesis by U. Karrer
problematic are primary infections during pregnancy with vertical transmission. 
Congenital HCMV-infection with a mortality rate of about 10% is characterized by 
transient jaundice, hepatosplenomegaly and thrombocytopenia and by persistent 
neurological defects and/or mental retardation in up to 80% of symptomatic cases (3). 
Primary HCMV-infection and more frequently reactivation of latent virus in 
immunocompromized individuals represent a second important clinical problem. 
Transplant recipients (bone marrow (BM), and solid organs) and AIDS-patients 
(particularly those with CD4^ T cell counts below 50 cells/pl) suffer from various 
manifestations of HCMV-disease including central nervous system infection and chorio­
retinitis, gastrointestinal and hepatobiliary syndromes and life-threatening pulmonary 
infection (3). Availability of antiviral drugs both against HCMV and HTV has 
contributed to a more favourable outcome of CMV-disease in immunocompromized 
patients. However, this achievement is restricted to developed countries where antiviral 
drugs are affordable.
2.2.2. Genome of Cytomegaloviruses
HCMV does not share significant nucleotide sequence homology with other CMVs 
including MCMV except for enhancer and genome packaging sequences (4). However, 
there is a far-reaching fimctional overlap between HCMV- and MCMV-derived proteins. 
Thus, positional and fimctional homologues exist between these two CMV (2). HCMV 
and MCMV share a similar genomic organization: they have a large (230-235kB) 
double-stranded, linear DNA-genome encoding > 200 open reading frames (ORF) (5). A 
core of genes, which are common to all herpesviruses, is arranged as gene blocks in the 
central lOOkB of the CMV-genome. Mainly ‘house keeping’ fimctions are encoded in
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these gene blocks including DNA-replication and repair, nucleotide metabolism or virion 
structure (2).
CMV-replication is tightly regulated in a multistep process, which is subdivided into 
immediate-early (IE), early (E) and late (L) phase of gene expression. lE-gene expression 
can be detected within 20-30 min after exposure of cells to virus (6). Two major gene 
products are transcribed from the lE-locus: lEl and IE2 in HCMV and lEl and IE3 in 
MCMV. In MCMV, a third gene product of the lE-locus, called IE2, is transcribed in the 
opposite direction. MCMV-IE2 whose function is unknown has been shown to be 
dispensable for in vitro and in vivo viral replication (7). Productive virus replication 
requires the expression of first lEl and then IE2 (HCMV) or IE3 (MCMV), respectively, 
since these gene products specify a crucial transactivator necessary for the expression E- 
and L-phase genes (8). During MCMV latency, transcription of lEl and somewhat less 
frequently of IE2 has been detected without evidence for full reactivation which is 
defined by the emergence of infective viral particles (8-10). This probably reflects the 
sporadic and intrinsic activity of the enhancer element controlling the lE l and IE2 
promoter (10). IE3 however, was not transcribed during latency but was only detectable 
if reactivation was promoted by immunosuppression or allogeneic stimulation (8,11).
2.2.3. Virion structure
Mature virions of CMV consist of an icosahedral capsid of about lOOnm diameter that is 
surrounded by a tegument or matrix. The capsid contains the viral genome, which is 
closely associated with core proteins forming the nucleocapsid. In addition, mature 
virions of 150-200nm have a host cell derived lipid bilayer envelope with several virally 
encoded glycoproteins (gp) (12). In tissue culture, cells infected with HCMV produce a
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substantial amount of defective viral particles called ‘dense bodies’ (DB), which lack a 
nucleocapsid and are largely composed of abundant tegument phospho-protein (pp) 
pp65/ppUL83 (pp65) with an envelope (13). In contrast, MCMV does not produce DB 
but has a propensity for multi-capsid-virions (14).
2.2.4. Viral proteins
2.2.4.1. Structural proteins
The HCMV-capsid is mainly composed of the major capsid protein (MCP/pUL86) and 
the minor capsid protein (mCP/pUL46), both exhibit low immunogenicity (15). The 
tegument proteins including ppl50/ppUL32 and particularly pp65 are immunologically 
more interesting since they are more immunogenic. Both elicit a readily detectable but 
not neutralizing antibody (Ab) response and have thus been used for sérodiagnostic 
purposes (16, 17). pp65 is highly abundant in the tegument of intact virions and even 
more so in DB which consist to 95% of pp65 (18). The exact function of pp65 is not 
clear yet but it was proposed to have an immune evasive function by inhibiting 
proteasomal processing of other HCMV-derived proteins like lEl (19). It is now clear 
that pp65 is a major target of the HCMV-specific CD8"^  cytotoxic T cell (CTL) response 
in persistently infected asymptomatic individuals (20-23) and several CTL-epitopes with 
differing restriction by the major histocompatibility complex (MHC) have been 
identified (24). CD8^ T cells specific for the other major tegument protein 
ppUL32/ppl50 of HCMV have also been identified but they are much rarer than pp65- 
specific cells (25).
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In mice, CD8^ T cells specific for the positional and functional homologues of pp65 
namely ppM83 and pM84 have been identified after MCMV-infection. However, the 
response seems to be much less prominent compared to pp65 in humans (26,27).
Virally encoded envelope glycoproteins (gp) are the major targets of the host’s 
neutralizing Ab-response in mice and men (15, 28). The major envelope gp of HCMV 
gB/gpUL55 (gB) plays a role in virion penetration of cells, transmission from cell to cell 
and fusion of infected cells (29). gB from HCMV and MCMV share extensive amino 
acid identity and antigenic crossreactivity (2, 30). Neutralizing Ab directed against gB 
can block all of the above mentioned functions of gB but neutralization is usually 
complement (C) dependent (31). HCMV-gB-derived epitopes for CDS’*" and CD4^ T 
cells have also been described (25, 32, 33). C-independent neutralizing Ab are mainly 
directed against a second HCMV-derived envelope glycoprotein called gH/gpUL75, 
which is involved in membrane fusion and cell-to-cell transmission of virus (34). There 
is little AA-sequence variation between different CMV-isolates within envelope gp (35). 
Therefore, most of the neutralizing Ab-epitopes of gB and gH are conserved and 
different serotypes have not been defined, although minor variations exist.
2.2.4.2. Regulatory proteins
Non structural regulatory CMV-proteins are highly relevant to understand the biology of 
the virus and its interactions with the host. CMVs are slowly replicating viruses with a 
rigid dsDNA-genome, which encode an estimate of up to 200 proteins. Therefore, they 
seem to be an easy prey for the host’s immune system. However, like other herpesviruses 
they have developed sophisticated strategies to prevent complete elimination by the 
immune system and to persist permanently for the lifetime of the host (2). The most
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important strategy of CMVs to persist is to hide from the immune system by latency. In 
latency, viral proteins, which are the major target for the immune system, are not 
produced (or only to a very limited extent). For transmission to a new host viral proteins 
have to be expressed and viral particles produced which then represent a target for the 
immune system. To limit this, CMVs encode a whole arsenal of genes interfering with 
the antiviral immune response (36).
Some of the important regulatory proteins of CMV replication and latency are encoded 
during the lE-phase of virus replication. HCMV-IEl/pp72 and MCMV-IEl/pp89 are 
major targets of the host’s antiviral CD8^ T cell response since they are usually 
expressed before the immune evasive genes become operational, which are mostly 
encoded during the E-phase of viral replication (25,32, 37, 38).
In recent years many fimctions of immune evasive proteins of CMV have been 
characterized on a molecular level. One of their mayor targets is the MHC class I Ag- 
presentation pathway. In MCMV, mainly three different proteins interfere profoundly 
with the cell’s Ag-presentation machinery. M06 binds to peptide-loaded MHC class I 
molecules in the endoplasmatic reticulum (ER) and redirects them to an 
endosomal/lysosomal compartment for degradation (39). M l52 triggers the retention of 
peptide loaded MHC class I complexes in an ER/Golgi intermediate compartment (40, 
41) and m04/gp34 escorts MHC class I complexes to the cell surface but seems to 
prevent their recognition by CD8^ T cells (42). It has been speculated that this might 
serve to silence NK-cells alerted by the lack of MHC class I expression on the surface of 
MCMV-infected cells (43).
In HCMV, US6 blocks peptide translocation through the transporter associated with Ag- 
presentation (TAP) (44, 45). US3, which is the only immune evasive protein expressed
17
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during the lE-phase of HCMV-replication, causes retention of MHC class I peptide 
complexes in the ER, which are then degraded by US2- and/or US 11-mediated 
mechanisms (46). hi addition, US2 and US 11 can mediate retrograde translocation of 
MHC class I molecules from the ER to the cytosol where they are rapidly degraded by 
the proteasome (47,48).
This profound downregulation of MHC class I molecules on the surface of infected cells 
could render these cells particularly vulnerable to NK-cell mediated destruction, which 
are activated by the ‘missing self (49). However, CMVs seem to have evolved 
additional strategies to avoid NK-cell mediated elimination (50). As an example, 
MCMV encodes the MHC class I homologue m l44, which has been shown to inhibit 
NK-cells mediated clearance of infected cells (51). Moreover, HCMV-derived UL40 
was shown to upregulate surface expression of HLA-E, a non classical MHC-molecule 
which is able to silence NK-cells (52).
2.2.5. Immune response after CMV-infection
Since CMV-infection does only lead to substantial morbidity and mortality in 
immunocompromised individuals, the immune response must be critically important in 
the control of overt disease. On the other hand we know that protective immunity is 
incomplete and viral persistence is invariably established upon primary infection. A 
delicate balance between virus and host has co-evolved permitting the survival and 
reproduction of both.
Most primary infections with CMV do not provoke sufficient clinical symptoms for 
patients to seek medical support. Therefore, these events are usually not recognized 
particularly during childhood. Some individuals develop a mononucleosis-like disease
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resembling acute Epstein Barr virus (EBV) infection with fever, lymphadenopathy, 
lymphocytosis and moderately elevated liver function tests (53). Probably, these 
symptomatic patients represent a selected population, where either the replication of 
CMV or the resulting immune response (or both) are more intense than in asymptomatic 
infection (54, 55). However, our knowledge about early events in HCMV-infection of 
immunocompetent individuals has been mainly gathered from studies of these 
symptomatic patients.
Transmission of CMV occurs by exchange of or exposure to blood and other body fluids 
like saliva, breast milk, urine and genital secretions. The incubation time from exposure 
to the onset of symptoms varies between 20-60 days. By then, virus is usually detectable 
in blood, pharyngeal swabs and urine. Plasma viremia is transient and below detectable 
levels within 2-3 weeks whereas pp65-antigenemia and particularly leukocyte associated 
viral DNA remains detectable for several months (56). Infectious virus can be recovered 
for several weeks from pharyngeal swabs and for up to one year from urine. HCMV 
excretion may be even substantially longer in children infected below 2 years of age (57, 
58).
Signs of a vigorous immune response during primary HCMV-infection of symptomatic 
patients are obvious on clinical examination (fever, lymphadenopathy, splenomegaly) 
and on a simple blood smear (lymphocytosis with ‘atypical’ cells). Most of these 
‘atypical’ lymphocytes belong to the CD8^ T cell compartment (59). Because of 
similarities to acute EBV-infection, where massive expansions of EBV-specific 
cytotoxic T cells (CTL) were demonstrated (60), it is speculated that these cells are 
mainly HCMV-specific CTL. However, a detailed analysis of the exact nature.
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magnitude, specificity and kinetics of the antiviral immune response during primary 
HCMV-infection has not been performed in immunocompetent individuals.
2.2.5.1. Innate immunity
In analogy to other viral infections and particularly because of data from the MCMV- 
model, innate immunity has been implicated in the control of primary HCMV-infection. 
Interest has focussed on natural killer (NK) cells since HCMV and MCMV encode 
several proteins with the capacity to interfere with NK cell activation (61, 62). 
Therefore, it seems likely that NK cells have exerted an evolutionary pressure on these 
viruses. In addition, patients with NK cell deficiencies concerning both number and 
function often develop severe infections with herpes viruses including HCMV (63, 64). 
However, direct evidence is limited concerning the exact role of NK cells in primary 
HCMV-infection and whether they form an important ‘first line of defence’ remains 
speculative.
In MCMV-infection, work from the group of R. Welsh suggested that NK cells limit 
early virus replication. Depletion of NK cells led to increased mortality due to 
uiurestricted vfral replication and dissemination (65). Analysis of resistant and 
susceptible strains of inbred and congenic mice led to the identification of an activating 
natural killer receptor called Ly49H which confers resistance to MCMV (66). Both 
direct cytolysis and interferon (IFN) y release of NK cells participate in the termination 
of productive MCMV-replication in an organ specific manner (67). In addition, NK cells 
together with T cells help to prevent MCMV-reactivation and thus maintain latency in a 
hierarchical and redundant fashion (68).
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The role of other cells of the innate immune system in HCMV-infection is less clear. 
Neutrophils are probably of minor importance since neutropenic individuals are not 
primarily prone to viral infections unless their lymphocyte number or function is 
suppressed as well (69). Macrophages seem to have a dual role: first, they are targets for 
virus replication and dissemination into tissues; second, they clearly exhibit antiviral 
functions both directly by the release of antiviral cytokines and chemokines and by 
activation of adaptive immune mechanisms (70). In MCMV their overall role in 
resistance is probably beneficial for the host whereas in HCMV this remains unclear 
since crucial experiments cannot be performed for obvious reasons (71).
Of all the different innate immune mechanisms based on soluble proteins, type I (ap) 
and type II (y) IFN seem to have the largest impact on CMV-replication, although 
clinical trials evaluating the effect of IFNy and IFNaP in the prevention or treatment of 
HCMV-infection have demonstrated veiy limited clinical benefit and a modest antiviral 
effect (72, 73). However, mice depleted of IFN in vivo or deficient for IFN receptors 
showed increased susceptibility after MCMV-infection (74). Particularly IFNap seems 
to be essential for early containment of viral replication and survival since receptor 
knock out animals died within 5 days after infection (75). IFNy-receptor deficient 
animals also show increased early susceptibility to MCMV-infection but they usually 
survive for several months but then develop lethal inflammation of the great vessels (76, 
77)).
Members of the tumour necrosis factor (TNF) family of proteins have a distinct 
influence on CMV replication. For HCMV, this was mainly analysed in vitro. While 
exogenous TNFa did not inhibit HCMV-replication in fibroblasts, lymphotoxin (LT)-a 
had a profound influence abolishing productive infection completely by increasing the
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production of IFNp (78). This seems to be similar in mice, since neutralization of TNFa 
or deficiency in the TNF-receptor 1 had only a minor influence on MCMV-replication 
(79, 80). In contrast, LTa-deficient mice were highly susceptible to MCMV -infection 
due to inefficient induction of IFNP-production (78).
Although the complement system is important for the action of CMV neutralizing 
antibodies in vitro there is no indication that this system is crucially involved in CMV 
control in vivo. However, as yet another immune evasive strategy of MCMV the 
membrane regulator of complement CD46 is upregulated in MCMV-infected cells 
leading to their protection from complement mediated lysis (81).
2.2.5.2. Adaptive immunity
Overall, the most important cells in immune control of CMV-infection are CD8'*’ T cells. 
Recovery from HCMV-disease coincides with emergence of virus specific CD8^ T cells 
in recipients of allogeneic bone marrow (82, 83). Both in humans and in mice adoptive 
transfer of CMV-specific CD 8  ^ T cells was sufficient to terminate productive virus 
replication and thus prevent CMV-disease an death in otherwise immunodeficient hosts 
(84, 85). In addition, using recently developed techniques to monitor T cell responses, 
large populations of HCMV-specific CD8’*’ T cells have been identified in asymptomatic 
seropositive individuals (21, 86-88). The size of these populations, which often reach 
several percentages of the total CD8^ T cell-pool, suggest an active involvement in long 
term control of the virus. However, in HCMV-infected young children, who shed 
infectious virus in urine and saliva for more than a year, HCMV-specific CD8^ T cells 
were found in similar frequencies compared to adults without evidence for productive
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viral replication (58). It has been speculated that CD8^ T cells might be preferentially 
responsible to limit systemic but not peripheral HCMV-replication.
The HCMV-specific CD8^ T cell-responses are mainly targeting two immunodominant 
proteins: the structural matrix protein pp65 and the regulatory protein IEl/pp72 (24). 
However, in contrast to EBV-infection, we completely lack data on the longitudinal 
evolution of HCMV-specific T cell responses in immunocompetent individuals, starting 
from primary infection. Therefore, we can only speculate how these responses develop.
In MCMV-infection, robust CD8^ T cell responses developing within 7-10 days have 
been described in detail by Reddehase and Koszinowski (89-91). Using classical ^^Cr- 
release and limiting dilution assays after in vitro restimulation to analyse cellular 
cytotoxicity, they could demonstrate CTL-activity from day 6 until several months after 
infection, when productive replication was long terminated. Dependent on the mouse 
strain analysed peptides from different proteins were shown to be immunodominant 
including one H2-D^-restricted epitope derived from IEl/pp89 (pp89). MCMV- 
homologues of the HCMV matrix protein pp65, which is immunodominant in humans, 
were clearly subdominant epitopes (24). Particularly in the BALB/c mouse strain, where 
the antiviral activity of NK cells is less dominant, CD8^ T cells have been shown to 
efficiently terminate productive infection. Furthermore, they were shown to be important 
for the maintenance of latency and the prevention of MCMV-reactivation, although NK 
cells and CD4^ T cells were ahle to compensate their absence (68).
A direct antiviral effect of CD4^ T cells is less well established and is mainly derived 
from studies in mice. In contrast to CD8^ T cells, adoptive transfer of CD4^ T cells from 
MCMV-infected immunocompetent mice failed to protect immunosuppressed animals 
against lethal MCMV-challenge (92, 93). However, in a situation of CD8^ T cell-
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deficiency primary infection with MCMV is cleared with similar efficacy by CD4^ T 
cells and NK cells and this protection against disease and death can be adoptively 
transferred to new hosts (94, 95). In addition, CD4^ T cells seem to have a unique role in 
the termination of productive viral infection in salivary glands and this antiviral effect is 
mediated by IFNy (96, 97).
In humans we know very little about the role of CD4^ T cells in immunity against 
HCMV. Substantial populations of HCMV-specific CD4^ T cells have been described in 
latently infected individuals but again we lack data on primary infection of 
immunocompetent individuals and their longitudinal follow up (98-100). In HCMV- 
infected young children shedding infectious virus in urine and saliva for more than a 
year, HCMV-specific CD4^ T cells were shown to secrete substantially less IFNy and IL- 
2 (101). However, whether this is an underlying reason for or a consequence of 
persistent viral replication remains unclear. In HIV-infected individuals with severe 
immunosuppression particularly those with a CD4^ T cell-count < 50 cells/pl, HCMV- 
reactivation is one of the major opportunistic infections and has been classified as an 
AIDS-defining disease. Since the number of CD4^ T cells in the blood correlates 
negatively with the risk for HCMV-disease, an important role for CD4^ T cells to 
prevent reactivation has been postulated (102). Furthermore, in HCMV-seronegative 
immunosuppressed recipients of a solid organ from a HCMV-seropositive donor, 
appearance of virus specific CD4^ T cells correlated better with disease resolution than 
reconstitution of CD8^ T cells (103, 104). However, it remains to be elucidated whether 
these are direct antiviral effects of CD4^ T cells or whether they fimction mainly by 
interacting with other cells, particularly CD8^ T cells.
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Both neutralizing and binding antibodies can be detected within weeks of primary 
infection with HCMV and neutralizing antibodies are mainly directed at the envelope GP 
gB and gH (15, 28). Most of their neutralizing activity is complement dependent (2). A 
role for neutralizing antibodies in the limitation of CMV-disease is suggested by several 
observations: first, preconceptional immunity usually protects newborns firom severe 
infection although not completely (105-107). Second, vertical transmission of the virus 
was less frequent in women with high titres of neutralizing antibodies (108). Third, the 
serum level of HCMV-neutralizing antibodies was inversely correlated with progression 
of CMV-retinitis in AIDS patients (109). Forth, clearance of HCMV-antigen from the 
blood was faster in those solid organ transplant recipients that produced high avidity 
antibodies (110). Last, survival of active HCMV-infection in allogeneic bone marrow 
recipients was associated with the level of anti-gB antibodies (111). However, some of 
these findings could also be explained by differences in cell-mediated immunity 
particularly concerning CD4^ T cells providing cognate help for HCMV-specific 
antibody responses.
In mice, antibodies were dispensable for clearance of primary infection but they were 
able to limit the systemic spread of recurrent MCMV-infection (112). Overall, 
neutralizing antibodies are probably most important during gestation and the early 
neonatal period to protect progeny from severe CMV-disease.
2.3. T cell responses during transient and persistent viral infections
Recent technological advances in the quantitative analyses of virus specific T cell 
responses have enabled us to quantify, monitor and analyse human T cells directly ex 
vivo. Studies using these methods have confirmed some earlier results, dismissed others
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and helped to generate several new concepts of T cell biology and homeostasis. 
Intracellular cytokine staining (ICS), enzyme linked immunospot assay (ELISpot) and 
major histocompatibility complex (MHC) class I tetrameric complexes (tetramer) have 
all been used to measure epitope specific T cells more accurately than with older 
techniques i.e. ^^Cr-release assay and limiting dilution analysis (see Chapter materials 
and methods for detail) (113). Particularly the development of tetramer and the 
subsequent analysis of the phenotype and the function of epitope specific CDS'*' T cells 
directly ex vivo has had an enormous impact on our understanding of virus specific 
immune responses (114, 115).
2.3.1. Bystander activation of T cells
It has been known for several decades that massive expansions of lymphocytes occur 
during acute infections. Most of these cells were assumed to be activated as ‘bystanders’ 
since their specificity could not be attributed to the infecting pathogen (116-118). 
However, the oligoclonal origin of these T cells in certain acute viral infections had 
already suggested that these expansions were dependent on interaction of the T cell 
receptor (TCR) with specific antigen and not driven by some unspecific ‘bystander’ 
signal (60, 119). This has been confirmed by studies using ICS, ELISpot and tetramer 
both in murine and human viral infections (120-123). In some acute viral infections like 
EBV in man or lymphocytic choriomeningitis virus (LCMV) in mice up to 50% of all 
CD8^ T cells can be specific for a single viral epitope. Overall, the magnitude of CD8^ T 
cell responses in viral infections measured with these new and more sensitive methods is 
about 10-fold larger than previously estimated (124). Therefore, the concept of bystander
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activation as an important factor in antiviral immune responses has been largely 
abandoned.
2.3.2 Clonal burst size and T cell memory
For transient infections, studies using tetramers confirmed a model that predicts the size 
of the memory T cell pool being dependent on the initial burst size of the response: the 
‘burst size model’ (120, 125). Usually, after initial expansion of effector T cells and 
subsequent clearance of the virus, the frequency of specific T cells drops and is then 
stabilized at a level of about 5-10% of the maximal frequency of T cells during the acute 
response. Although this general rule has been generally confirmed, the quantitative 
analysis of antiviral T cell responses with newer techniques revealed frequencies which 
are about 10 times higher than what was estimated with older measurements both during 
acute infection and also in memory (120, 126). Not surprisingly, there are certain 
exceptions: in persistent infections epitope specific T cells persist at higher frequencies 
than anticipated from the size of the primary response (126, 127).
2.3.3. T cell responses against viruses that persist at high levels
Studies of persistent infections in mice and in humans have revealed that the amount of 
virus persisting in a host has a fundamental influence on the resulting T cell response. 
Examples of high level persistence like chronic HIV- or HCV-infection in humans and 
certain virus isolates of lymphocytic choriomeningitis virus (LCMV)-infection in mice, 
as well as examples of low level persistence like EBV- or HCMV-infection in humans 
and murine y-herpesvirus 68 (MHV-68) or MCMV-infection in mice will be discussed in 
the following section.
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The level of persistence is obviously dependent on the biology of the virus. Viruses with 
a high cytopathogenicity cannot persist at a high level for prolonged time periods 
without killing the host, and thus jeopardizing their own survival. Therefore, nearly all 
viruses capable of high level persistence are poorly cytopathic or, as an exception, they 
infect cells that are not required for host survival (128). In addition, most viruses capable 
of high-level persistence have a rather small genome and a high replication rate. Overall, 
their strategy to persist despite the defence mechanisms of the host is one of ‘speed’ and 
‘shape change’ (129). Nevertheless, the immune response seems to have an important 
impact on the outcome of these infections.
2.3.3.1. T cell responses in HlV-infection
m v  mainly infects activated CD4^ T cells via CD4 and a co-receptor (130-132). During 
the course of the infection CD4^ T cells are gradually lost and progressive 
immunodeficiency develops in infected individuals. The most important clinical 
parameters predicting the prognosis of an HTV-infected individual after resolution of 
primary infection are the CD4-count and the ‘set point’ virus load (VL): the probability 
of disease free survival increases with higher CD4-counts and lower VL (133). However, 
in the natural course of infection nearly all infected people develop AIDS, which is 
characterized by an increased susceptibility to opportunistic infections and tumours. It 
was recognized early on that a shong antiviral immune response was active during all 
phases of HIV-infection. An important role for HTV-specific CD8^ T cells has been 
suggested by several different studies over time. First, it was noted that the appearance 
of HTV-specific CD8^ T cells during primary HIV-infection was associated with a drop 
in viremia to the ‘set-point’ VL (119, 134, 135). In chronic infection the level of CTL-
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reactivity was inversely correlated with VL, CD4^ T cell-decline and disease progression 
(136). In addition, HTV-specific CTL seem to exert an important evolutionary pressure 
on the virus, since CTL-escape mutations fi-equently occur in different phases of the 
infection, and they can be associated with loss of immune control (137, 138). However, 
the most convincing evidence for CD8^ T cell-mediated immune control of HIV comes 
fi"om experiments performed in macaques infected with the simian immunodeficiency 
virus (STV), which is closely related to HTV. Upon in vivo depletion of CD8^ T cells 
with monoclonal antibodies, a sharp rise in STV viremia and a rapid progression to 
simian AIDS was observed (139, 140).
After identification of large populations of specific CD8^ T cells both in acute and 
chronic HTV-infection, the question arises, why these cells cannot control the virus in the 
long term in most infected individuals. Many different mechanisms have been postulated 
and some have been demonstrated experimentally, but usually in a restricted set of 
individuals (reviewed in (141)): 1) Viral escape by selection of mutations of 
immunodominant CTL-epitopes and subsequent loss of immune control was recognized 
early on in different phases of the disease course and has since been repetitively 
confirmed (137, 142). 2) Maintenance of CTL-activity in persistent infections is 
probably dependent on virus specific CD4^ T helper cells, and they seem to be 
preferentially infected by HTV and possibly lost already during primary infection (143- 
145). 3) HTV-specific CD8^ T cells might be deleted in phases of high viral replication 
due to clonal exhaustion (146-148). 4) Anergic CD8^ T cells with defective reactivity to 
antigen have been found repetitively in chronic HTV-infection (149-151). 5) Lack of 
perforin expression in HTV-specific CD8^ T cells and thus poor cytotoxicity has also 
been implicated in HIV-pathogenesis (152). 6) In late stage infection the release of IFNy
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by CD8^ T cells was also affected (153, 154). 7) Inefficient homing of HTV-specific 
CD8^ T cells to lymphnodes (LN) has been postulated to cause poor viral control of an 
important viral reservoir in LN, since the phenotypic analyses of HTV-specific tetramer 
positive cells revealed the absence of the LN-homing markers CD62L and CCR7 (141, 
155). 8) CD8^ T cells from HIV-infected patients showed defects in TCR mediated 
signalling and in expression of the costimulatory molecule CD28 (156-158). 9) ‘Skewed’ 
or incomplete maturation of HTV-specific memory T cells devoid of important effector 
functions has also been correlated with poor viral control (159,160).
However, this list is by no means complete and the relative importance of each of these 
(and other) mechanisms to explain the failure of CD 8  ^T cell mediated immune control 
of HTV-infection is largely unclear but most likely multifactorial. It remains very 
difficult to differentiate in a natural human infection between important pathogenic 
factors and epiphenomena. Ideally, established parameters of an infection, which are 
predictive of disease progression and outcome (i.e. VL and CD4-count in HTV- 
infection), are used to correlate with the measured variables. However, in immunologic 
studies of human viral infections certain key variables, which can crucially influence the 
outcome of a virus-host interaction, are not known or might be widely distributed 
between individuals of a ‘experimental group’. These include parameters of the virus 
itself (infectious dose, pathogenicity, cellular tropism, virulence and subtype or strain), 
circumstances of the infection (exact time point and route of infection) and, in addition, 
genetic and other host factors.
2.33.2. Tcell responses in LCMV-infection
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Some of these variables can be controlled in mouse models of persistent infection. These 
models have clearly shown, that the basic parameters mentioned above have a crucial 
influence on the outcome of a virus-host interaction (161, 162). LCMV, which is one of 
the most widely used viral models in mice, is a poorly cytopathic arenavirus and the 
mouse is its natural host (163). It replicates widely in many different cell types and 
organs, but the infection is usually cleared in immunocompetent mice below the limit of 
detection (<50 plaque forming units (PFU) / ml blood) within 10-20 days by a vigorous 
and perforin dependent CTL-response (164). Nevertheless, virus does persist at very low 
levels despite a high frequency of CD8^ memory T cells (120,165). The development of 
a neutralizing antibody response seems to be necessary to prevent re-emergence of the 
virus late after infection (166, 167). Therefore, initial virus control is CTL-mediated, 
whereas long term control probably requires the coordinate action of all arms of the 
adaptive immune system.
However, infection of mice with a high dose of virulent (fast replicating) virus given 
systemically (i.v.), leads to high level virus persistence (> 10  ^ PFU / ml blood) by 
exhaustion of certain epitope specific CD8^ T cells and anergy of others (146, 168, 169). 
Thus, these simple parameters (virus strain, dose and route of infection) determine the 
outcome of LCMV-infection - clearance of virus to very low levels with strong CTL- 
memory - or high-level virus persistence with deletion and/or anergy of specific CTL. 
Like this, LCMV has been used as a model for low level or high-level virus persistence. 
Furthermore, the exhaustive induction of virus specific CD 8"^  T cells is greatly facilitated 
by a lack of specific CD4^ T cell help (170, 171). It was speculated for a long time, that 
maintenance of functional LCMV-specific CTL depends on the presence of CD4^ T cells 
(172, 173). However, a recent analysis revealed that neutralizing antibodies and not T
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helper cells provided the necessary additional factor needed for long term control of 
LCMV (167). This is surprising in the light of the fact that CD4^ T cells were shown to 
be crucial for CDS'*’ T cells during the initial phase of antigen contact. Without T cell 
help in the primary response, CD8^ T cells failed to expand upon a second exposure to 
the same antigen (174-177). Since persistent infections are characterized by continuous 
exposure to antigen with the need for permanent ‘secondary’ responses, it would be 
expected that CD4^ T cell-deficiency leads to a failure of immune control in persistent 
infections.
Only in high level LCMV -persistence with viral titres remaining constantly in the range 
of lO'^ -lO^  PFU/ml blood, deletion or dysfunction of specific CD8^ T cells was observed 
(168, 169). In low level persistence (< 50PFU/ml blood) LCMV-specific memory CD8^ 
T cells have excellent effector function and protective capacity unless the neutralizing 
Ab-response is prevented (166,167).
2.3.4. T cell responses against viruses that persist at low levels
Herpesviruses are the prototype of viruses that persist at low levels. Since they are 
cytopathic, they have evolved the strategy of latency to survive in a host without causing 
permanent damage, and the strategy of reactivation to enable transmission to a new host. 
They have a large and rather stable genome of dsDNA, they replicate slowly and they 
encode between 100-200 different proteins, which provide many targets for the host’s 
immune system. Nevertheless, they are evolutionary very successful, since most 
individuals harbour more than one herpesvirus, and they persist indefinitely in their 
respective hosts. During primary infection and reactivation they are visible for the host’s 
immune system but not during latency (or only to a very limited extent). Their strategy of
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immune evasion is one of ‘camouflage’ and ‘sabotage’ enabling them to persist despite a 
vigorous immune response (129).
2.3.4.L Tcells in EBV-infection
EBV is a y-herpesvirus that mainly infects B cells via the complement receptor CD21 
(178). Primary infection is usually acquired in childhood by transmission of virus in 
saliva. Interestingly, the age at the time of infection has an influence on clinical 
symptoms. The syndrome of infectious mononucleosis usually occurs in older children 
and young adults and only rarely in children infected at young age, most probably 
because of a less intense T cell response (179). Tetramer based analysis of the EBV- 
specific CD8^ T cell-response in infectious mononucleosis disclosed extremely high 
frequencies of EBV-specifrc T cells, which are mostly directed against proteins 
expressed during the lytic cycle of infection (122, 127). After resolution of primary 
infection and termination of the lytic cycle these responses are culled substantially and 
asymmetrically, which is not in agreement with the burst size model mentioned earlier 
(180). Sometimes they seem to be lost completely which is surprising, since viral 
reactivation with reexpression of lytic proteins frequently occurs to allow transmission to 
a new host. However, a different evolution has been described for CD8^ T cells specific 
for latent epitopes of EBV (127, 181). These responses develop more slowly and are 
mostly subdominant during acute infection. Later on they become the dominant 
responses in asymptomatic virus carriers. Although the virus has evolved a strategy to 
protect the most abundantly expressed latent protein EBNA-1 from CD8^ T cell attack 
by preventing its degradation by the proteasome (182), the EBV specific T cell response 
seems still to be important for the host also during latent infection. EBV-associated B
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cell lymphomas are much more frequent in people which are immunosuppressed due to 
HTV-infection or after transplantation. In contrast to HTV-infection, there is no indication 
that EBV-specifrc CD8^ T cells are dysfunctional at any stage of the infection in 
otherwise immunocompetent individuals (127).
23.4.2. Tcells after infection with murine /-Herpesvirus-68 (MHV-68)
Infection of mice with the murine y-Herpesvirus-68 (MHV-68) leads to a syndrome, 
which has similarities to EBV-infection in humans. The virus has a lytic and a latent 
replication cycle and persists mainly in B cells and macrophages. Late after infection 
about 10% of infected animals develop lymphoproliferative disease originating from B 
cells (183). The CD8^ T cell response is crucial for the initial termination of productive 
infection in the lungs (184). However, mice deficient for CD4^ T cells cannot maintain 
protective immunity and the virus reactivates mainly in the lung, leading to death after 
100-120 days despite a prominent CD8^ T cell response which seems to be fully 
functional (185,186). Again, the T help dependent neutralizing Ab-response seems to be 
more crucial than a direct antiviral effect of CD4^ T cells (183). However, analysis of B 
cell deficient mice is complicated by the fact, that B cells are a principal source of latent 
MHV-68.
Careful experiments comparing the CD8^ T cell response against a transient (i.e. 
influenza A virus) and a persistent respiratory infection (MHV-68) revealed no 
important differences during the acute phase of the response. During the memory phase 
the frequency, certain markers of activation and the rate of turnover of CD 8  ^ T cells 
remained higher in persistent infection than after complete resolution of transient 
infection (126).
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Overall, these studies of T cells in persistent viral infections suggest that high level 
persistence of a virus has profound and usually detrimental consequences for antiviral 
CDS'*’ T cells leading to deletion, exhaustion and/or anergy. This negative outcome 
seems to be enhanced by a lack of specific CD4^ T cell help or by a lack of neutralizing 
Ab.
Persistence of viruses at very low levels or their intermittent reactivation leaves the virus 
specific CD8^ T cell response phenotypically and functionally intact. There are increases 
in T cell frequency, activation level and rate of turnover without evidence for specific 
defects. However, lack of CD4^ T cells can also lead to loss of CD8  ^T cell-mediated 
viral control in low level persistent infections (166, 185, 186). However, it remains to be 
analysed whether subtle functional defects of CD8^ T cells precede the re-emergence of 
viral progeny.
In our study we have analysed the course of the CD8'*’ T cell response during MCMV- 
infection of immunocompetent mice using modem immunological techniques. Our 
results, gained in a well-defined model of low-level persistent viral infection, contribute 
to the increasing knowledge about the interplay between viruses and their natural hosts. 
A unique pattern of a virus specific immune response emerged from this analysis and we 
propose an explanation for these findings, which is mainly based on the particular 
biology of CMV. We have performed additional experiments with recombinant MCMV, 
which suggest a possible way to harness the biology of these viruses for vaccine 
purposes. Finally, we try to put our results into a broader immunologic context of our 
current understanding how protective immunity is best maintained.
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3. Material and Methods
3.1. Mice and animal experiments
Mice were purchased from Biomedical Services Unit, John Radcliffe Hospital, Oxford, 
UK. Animals were bred under specific pathogen free conditions and housed in a 
controlled conventional unit during the experiments. All animal experiments were 
performed with age-matched female BALB/c and C57BL/6 mice with permission of the 
home office according to the Animals (Scientific Procedures) Act 1986 (UK), requiring 
the use of minimal numbers of animals. Mice were infected with a volume of 200 pi 
virus in PBS i.v. (MCMV, LCMV and W )  or i.p. (W ), or with 20 pi virus in PBS 
intranasally (influenza). The infectious dose is indicated in the text or figure legend. A 
short (< Imin) anaesthesia with ether was applied for intranasal influenza infection. For 
s.c. immunization with peptide, 200 pg of peptide was solubilized in 100 pi PBS and 
then emulsified in 100 pi of CFA. For flow cytometry, a 50 pi blood-sample was taken 
from the tail vein.
Organs were prepared after intravenous perfusion with 15-20 ml PBS (4°C) immediately 
after sacrifice, followed by preparation of single cell suspensions by disruption of organs 
over a fine metal grid within Ihr. To separate lymphocytes, liver preparations were then 
centrifuged over Percoll (Sigma-Aldrich, Poole, UK) before staining. Other organ 
suspensions were centrifuged once to remove debris and directly used for staining and 
flow cytometric analysis. Broncho-alveolar lavage was performed by insertion of a fine 
canula into the trachea after perfusion, followed by direct lavage of PBS into the lungs. 
Cells were centrifuged and used directly for staining and flow cytometric analysis.
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3.2. Viruses
MCMV (Smith strain, ATCC: VR-194) and Vac89 (187) were provided by Prof. U.H. 
Koszinowski, Max von Pettenkofer Institute, Department of Virology, Munich, 
Germany. MCMV was grown on mouse embryonic fibroblasts (MEF) and purified by 
sucrose gradient centrifugation according to established protocols (188). MCMV titres of 
virus stocks and organ homogenates were determined by virus plaque assays on MEF as 
described using centrifugal enhancement of infectivity (188). Titres are expressed as 
logio(PFU MCMV/organ). The detection limits of the assays are indicated in the figure 
legend. Influenza A virus H17 was provided by Dr Keith Gould, Imperial College, 
London. VacNP was provided by Prof. A. Townsend, Weatherall Institute of Molecular 
Medicine, Oxford, UK., and VacGP by Prof. B. Moss, Laboratory of Viral Diseases, 
National Institute of Health, Bethesda, MD (189, 190). Recombinant W  were grown 
and viral titres were measured by virus plaque assay on TK' (thymidine kinase deficient) 
cells. Diluted and sonicated lysates of TK" cells were used for infection. A single stock 
or the respective virus was used for the majority of experiments, importantly those 
following development of immunity over time.
3.2.1. Generation of recombinant MCMV
Recombinant MCMV were designed for the purpose of this project. They were generated 
according to a recently established protocol by Dr. Markus Wagner in the research lab of 
Professor Ulrich H. Koszinowski (Max Pettenkofer Institute in Munich, Germany (191)). 
Recombinant MCMV with a C-terminal fusion of the LCMV-derived GP33-41 or the 
Influenza-derived NP366-374 peptides (see below) to the non-essential ie2-gene of 
MCMV were generated using a new mutagenesis procedure for the MCMV genome
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cloned as bacterial artificial chromosome (pSMSfi*) in E. coli (192). It was shown that 
virus, reconstituted from the BAG genome pSM3fr, shows wild type-virus-like 
replication properties and cellular tropism in vitro and in vivo (193). For generation of 
the recombinant viruses MCMV-GP and MCMV-NP, two linear DNA fragments 
containing a kanamycin resistance gene, homologies of about 40 nts to the up- and 
downstream sequences of the stop codon of the ie2 gene, and the GP33-41 or NP366- 
374 sequence, respectively, were generated by PCR. For generation of the fragment 
containing the GP33-42 sequence (and additional 6 flanking nts on each side) the 
contiguous primers ie2-LCMV-5 (5’-GAACCACGG GTTCTTTCT CTTGACCAG 
AGACCTGGT GACCGTCAG GAAGAAGAT TCAGGGTAT CAAGGCTGTC
TACAATTTT GCCACCTGT GGGATATGA CGATTTATTC AACAAAGCC ACG- 
3’) (GP33-41 underlined) and ie2-Kn-3 (5’-CTGTCCGAT GAATAAAAC
CTCTTTATT TATTGATTA AAAACCATG ACATACCTC GTGTCCTCG
CCAGTGTTA CAACCAATT AACC-3), and the template plasmid pACYC177 (NEB) 
were used for PCR. For generation of the fragment containing the NP366-374 sequence 
(and additional 6 flanking nts on each side) the contiguous primers ie2-Flu-5 (5’- 
GAACCACGG GTTCTTTCT CTTGACCAG AGACCTGGT GACCGTCAG
GAAGAAGAT TCAGCAAAT TGCTTCAAAT GAAAACATG GATGCTATG
GAATCATGA CGATTTATT CAACAAAGC CACG-3’) (NP366-374 underlined) and 
ie2-Kn-3 (see above), and plasmid pACYC177 were used for PCR. The fragment was 
then transformed into DHIOB for mutagenesis of the MCMV-BAC pSM3fr, which 
contains the whole MCMV genome (strain smith). Mutagenesis was performed 
following a recently published protocol that uses homologous recombination mediated 
by the recombination functions redaP from bacteriophage X (194). Correct fusion of the
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epitope sequences to the C-terminus of the ie2 gene within the viral genomes was 
confirmed by restriction pattern analysis of the recombinant MCMV BAC with Nsil and 
by additional sequencing of the ie2-epitope fusion (data not shown). Expression of the 
IE2-epitope fusion was also confirmed by Western blot analysis (Fig 2A).
3.3. Peptides and tetramers
The following peptides defining MCMV-derived CDS'*’ T cell-epitopes in the MHC- 
haplotype H2^ from 5 different MCMV proteins were used: ml23/pp89 (pp89, H2-L^- 
restricted, ^^^YPHFMPTNL^^  ^ (37)), m04/gp34 (m04, H2-D‘^ -restricted,
^^^YGPSLYRRF^^  ^ (195)), M84/p65 (M84, H2-K"^-restricted, ^^^AYAGLFTPL^°^ (26)), 
M83/ppl05 (M83, H2-L"^-restricted, ^^^YPSKEPFNF^^  ^(27)) and ml64 (m l64, H2-D‘*- 
restricted, ^^^AGPPRYSRI^^  ^ (196). As a negative control, a peptide derived from an 
endogenous retrovirus of the murine CT26 colon carcinoma cell line was used (CTpep, 
H2-L^-restricted, SPSYVYHQF) (197). The following peptides defining LCMV and 
influenza derived CTL-epitopes were used: LCMV-GP (GP33-41, KAVYNFATC, H2- 
D^-restricted (198) or GP34-41, AVYNFATC, H2-K^-restricted (199)) and influenza-NP 
(NP366-374, ASNEMNDAM, H2-D^-restricted (189). Peptides were synthesized at a 
purity of >70% (Research Genetics, Huntsville, AL), diluted and used at the indicated 
concentrations.
The tetramers used in this study were produced as described (114). Briefly, recombinant 
H2-L^, H2-D^ and H2-K^-heavy chain were expressed in E. coli (BL21), purified from 
inclusion bodies, biotinylated enzymatically and refolded with human p2-microglobulin 
and the appropriate peptide. Plasmids encoding for the different MHC class I heavy 
chains were generously provided by Awen Gallimore (Oxford University, UK) and John
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D. Altman (Stanford University, CA). Refolded complexes were purified by HPLC and 
tetramerized using PE-labelled extravidin (Sigma-Aldrich, Poole, UK) at a molar ratio of 
4:1. Specificity and sensitivity of tetramers was regularly tested on CTL-lines 
restimulated with the appropriate peptide. The control CT-tetramer was generously 
provided by Dr. A. Gallimore, John Radcliffe Hospital, Oxford, UK. In all experiments 
background staining with CT-tetramer was < 0.1% of CD8^ T cells (not shown).
Fifty pi of peripheral blood or 2x10^-10^ nucleated cells from spleen, liver, lymph node, 
salivary gland and lung broncho-alveolar lavage (BAL) were prepared in cold PBS 
containing 2% PCS, 0.2% NaN^ and 10 mM EDTA. Cells were stained for 20 min at 
37°C with pp89- or CT-tetramer. Surface markers were quantified by staining for 30 min 
at 4°C with the following Ab (purchased from BD, San Jose, CA.): APC- or PerCP- 
labeled rat anti-mouse CD8 (clone 53-6.7), PerCP- or FITC-labeled rat anti-mouse 
CD45R/B220 (clone RA3-6B2), FITC-labelled rat anti-mouse CD18 (clone C71/16), 
FITC-labelled rat anti-mouse CD25 (clone 7D4), FITC-labelled rat anti-mouse CD43^ ®^  ^
(clone IB 11), FITC-labelled rat anti-mouse CD44 (PgP-1, clone IM7), APC- or FITC- 
labelled rat anti-mouse CD62L (MEL-14), and a panel of FITC-labelled antibodies 
specific for the variable region of TCR (3-chains (V(3). FITC-labelled hamster anti-mouse 
CD69 (clone H1.2F3) was purchased from Serotec Ltd. Oxford, UK. FITC-labelled rat 
IgG2a (BD) and hamster IgG (Serotec) isotype controls were used for gate settings. 
Analysis was performed as described above.
3.4. Assessment of IFN-y-secreting peptide-specific CDS'*' T lymphocyte frequencies
Frequencies of IFNy-producing peptide specific T cells in the spleen were quantified by 
intracellular IFNy staining after stimulation with peptide (ICS) according to the protocols
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of the supplier of reagents (Becton Dickinson, San Jose, CA. (BD)). After 6h peptide
(10‘^  M) stimulation, spleen cells were stained with allophycocyanin or PerCP^-labelled 
rat anti-mouse CDS (clone 53-6.7), fixed and permeabilized and then stained with FITC- 
labelled rat anti-mouse IFNy (clone XMG1.2) or with an FITC-labelled rat IgG 1-isotype
control Ab. Samples were analysed with a FACSCalibur® (BD) using Cell Quest® 
software. Gates were set according to the isotope control and firequencies are given as 
percentage of IFNy-secreting cells of total CDS'*’ T cells. Background staining for IFNy 
was below 0.05% of CD8^ T cells after stimulation with irrelevant peptides and after 
stimulation of cells from naïve mice.
Within the region of LCMV-GP, that is shared between MCMV-GP, VacGP and the 
peptide GP33-41 (^^KAVYNFATC^^) used for immunization, two differentially 
restricted CD8^ T cell-epitopes exist in the H2*’-haplotype: H2-D'’-restricted GP33-41 
and H2-K^-restricted GP34-41 (198, 199). After in vitro stimulation with 
KAVYNFATC, specific CD8^ T cells with either MHC-restriction produce IFNy, thus 
these percentages are the sum of GP33 and GP34-specific cells.
3.5. Assessment of MCMV-specific cytotoxic activity in vitro
CTL-activity of spleen cells was determined by ^^Cr-release assay as described (190). 
Effector spleen cells were restimulated for 5 days in vitro with peptide pulsed (10'^ M) 
and y-irradiated (25 Gy) spleen cells. Serial dilutions of bulk cultures were incubated for 
5h with ^‘Cr-labelled and peptide pulsed (10'^ M) EL4 target cells (H2^) and the 
supernatant was assayed for released ^^Cr. Spontaneous ^^Cr-release and unspecific lysis 
of target cells pulsed with irrelevant peptides was below 15% in all assays.
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3.6. Bromo-deoxy-uridine (BrDU) labelling and calculation of cycling cell 
populations
Mice were treated with 0.8 mg/ml BrdU in the drinking water and injected daily with 1 
mg of BrdU i.p. for 10 days. After 10 days the spleens were removed and tetramer 
staining was performed as above. BrDU staining was performed after permeabilisation 
of cells using a BrDU labelling kit according to manufacturer’s instructions (BD, San 
Jose, CA).
3.7. In vivo protection assay
The ovary protection assay was performed as described (200). Briefly, mice previously 
infected or immunized as indicated in the text were challenged with 5x10^ PFU 
recombinant W  i.p. Four days later, ovaries were homogenized and W -titre was 
measured by virus plaque assay on TK'-cells. Titres are expressed as logio(PFU 
W/organ). The detection limit was 40 PFU W /ovary in all allays. The level of 
protection is given as the percentage of virus titre reduction in the respective 
experimental group compared to age-matched naïve mice or mice infected or immunized 
with an unrelated virus/Ag.
3.8. Calculation of correlation between the frequencies of epitope-specific CDS  ^T 
cells, the level of protection and the time after priming
Mice were primed with the indicated viruses and the frequency of epitope-specific CD8^ 
T cells was measured in the blood 0-3 days before challenge with recombinant W .  Four 
days after challenge W -titres were determined in the ovaries of immunized and naïve 
age-matched mice. The level of protection was calculated by subtracting the logioPFU
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W -titre of the immunized mice from the mean logioPFU W -titre of the naïve group of 
mice. The frequency of epitope-specific CD8^ T cells before challenge was then 
correlated with the level of protection and the time since priming. In addition, the level 
of protection was correlated with the time since priming. Correlations were calculated 
using Spearman’s rank correlation using a logarithmic scale. The number of animals 
included into the calculations is indicated in the table.
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4. Results
4.1. Chapter 1
Memory inflation: continuous accumulation of antiviral CDS’*" T cells over time.
4.1.1. Summary
CDS'*' T lymphocytes play an important role in the control of intracellular pathogens, 
both during acute and persistent infections. This is particularly true in the case of 
persistent herpesviruses such as human cytomegalovirus (HCMV), which are typified by 
large virus-specific CDS'*’ T cell populations during viral latency. To understand the 
origin of these populations and the factors shaping them over time, we investigated the 
CD8^ T cell-response after murine cytomegalovirus (MCMV) infection. The kinetics of 
the acute response was characterized by rapid expansion of activated T cells, followed by 
a contraction phase. Thereafter, we observed a striking pattern, where MCMV-specific 
memory CD8'*’ T cells steadily accumulated over time, with 20% of all CD8^ T cells at 
one year specific for one MCMV epitope. Accumulation of MCMV-specific CD8^ T 
lymphocytes was seen in all organs tested and was associated with continuous activation 
of specific CD8^ T lymphocytes, primarily within lymph nodes. The pattern of 
accumulation was observed only in two out of five epitopes tested, and was accompanied 
by a gradual restriction in T cell receptor Vp chain usage over time. This novel pattern of 
a virus-specific CD8'*’ T cell-response suggests that continuous or repetitive exposure to 
antigen can slowly mould memory T cell populations over time. This may be relevant for 
understanding of the evolution of the large HCMV-specific CD8'*’ T cell populations 
seen in humans.
44
MCMV as a model for persistent viral infection PhD-Thesis by U. Karrer
4.1.2. Introduction
To analyse the CD8^ T cell-response to another important persistent virus with 
contemporary methods, we have characterized the CD8^ T cell-response after infection 
with MCMV in detail using a combination of phenotypic and functional assays. We 
focused on the immunodominant CD8'*’ T cell-response directed against the IE 1-protein 
ml23/pp89 (pp89) after infection with MCMV and compared it to the same response 
generated after infection with a non persistent recombinant Vaccinia virus (W ) 
expressing pp89 (Vac89, (187)). We have also analysed responses directed against other 
recently described CD8^ T cell-epitopes, which are not derived from IE-1. The results 
presented here suggest that apparently latent MCMV has a continuous and profound 
influence on the frequency, phenotype and distribution of MCMV-specific CD8^ T cells 
and give an insight into the possible evolution of CMV-specific T cell responses in 
humans.
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4.1.3. Results
4.1.3.1. Accumulation o f functionalpp89-speciflc CD8^ T cells after MCMV-infection 
Initial experiments were performed to correlate the immune response against MCMV 
with the kinetics of viral production. The titre of replicating MCMV was determined by 
virus plaque assay (Fig. lA for spleen and salivary gland; liver and lung not shown). In 
the spleen and liver the peak MCMV titre was reached 3 days after infection with titres 
falling below the limit of detection by day 12. In the lungs and salivary glands the peak 
was about a week later (day 10-15), and the decline slightly slower. By day 40, 
replicating virus was detectable only in salivary gland tissue in 33% of the infected mice. 
At all time points thereafter (day 75-400), productive MCMV-replication was below the 
detection limit for all organs tested. Thus, while the kinetics of viral growth and decline 
differed in different organs, after about 8-10 weeks replicating virus was no longer 
detectable.
We next measured the firequency of H-2L^ restricted, pp89-specific CD8^ T cells by 
tetramer staining (pp89-tet) or intracellular cytokine staining for IFNy (pp89- IFNy) after 
infection of BALB/c-mice with MCMV or Vac89. W  does not persist or reactivate after 
resolution of primary infection in immunocompetent mice (201) whereas MCMV 
establishes a latent infection in many sites with a continuous potential for reactivation 
(2). We thus compared the frequencies of CD8^ T cells directed against the same epitope 
following two different infections.
In the blood, an initial peak of 5.9% of pp89-specific was reached 8 days after MCMV- 
infection. A contraction phase then ensued and frequencies declined to 3.4% at day 15 
and were maintained at this level until day 40 (3.7%). Remarkably, thereafter pp89- 
specific CD8^ T cell-frequencies began to rise again at a time when replicating MCMV
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was no longer detectable. More than 20% of CD8^ T cells were specific for this single 
viral epitope 400 days after MCMV-infection (Fig. IB).
In the spleen, a similar “biphasic” pattern was observed. Initial expansion of pp89- 
specific CD8^ T cells peaking at day 8-10 (5.9%) was followed by a contraction phase 
and firom day 40 onwards a gradual increase in pp89-specific T cells. By day 400 15.3% 
of CD8^ T cells were specific for pp89 by tetramer staining and at least 80% of these 
cells produced IFNy within 6h of antigen recognition (Fig. 1C). After an initial 
expansion and only limited contraction phase an accumulation of the total number of 
pp89-specific cells per spleen was also observed from day 40 to day 400 by 2-3-fold 
(Fig. ID).
In contrast, after infection with Vac89, the peak of the pp89-specific CD8^ T cell- 
response was reached between day 6 and day 9 (2% of CD8  ^T cells tetramer positive). 
By day 28 the frequencies had halved and were maintained at a constant level thereafter 
(about 0.7% of CD8^ T cells). Similar results were obtained using both tetramer and 
intracellular cytokine staining (Fig. IB-E).
This accumulation of virus specific CD8^ T cells after MCMV infection was not 
restricted to the blood and spleen, as a similar pattern was observed in other organs. We 
analysed the frequency of pp89-specific CD8^ T cells in lymph nodes (cervical, 
mesenteric and axillary) and in organ infiltrates from liver, lung (BAL) and salivary 
gland over time with an increase in frequency during viral latency seen in all cases (Fig 
2A). Additional data from other organs including ovaries, adrenal glands and bone 
marrow confirmed this general pattern (data not shown). Thus during latency, there is an 
accumulation in multiple body compartments of pp89-specific CD8^ T lymphocytes in
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terms of both frequency amongst CD8^ T lymphocytes and absolute numbers (Table 1, 
Fig ID).
4.1.3.2. Oligoclonality o f pp89-specific CD8^ T lymphocyte population
We next addressed the issue of whether these expanding populations represented the 
accumulation of polyclonal CD8^ T lymphocyte populations, or oligoclonal populations 
with restricted TCR usage (as has been observed in HCMV (22, 202)). To study this 
directly ex vivo, we identified pp89-specific T cells using the tetramer and co-stained 
with a panel of Vp specific TCR antibodies. We analysed the proportions of pp89- 
specific cells, which expressed TCRs of different Vp-types over time. This experiment 
(Fig 2B) shows at later time points an increase in the proportion of the tetramer positive 
population, which use the Vp 8.1 TCR chain. Early after MCMV infection (day 8-12), 
pp89-specific T cells used a diverse set of Vp TCR chains. The Vp 8.1/8.2 usage 
amongst the pp89-specific T cell population then increased over time: about half the 
tetramer positive population expressed Vp 8.1 or 8.2 by day 270. As a negative control, 
Vp-specifrc TCRs (e.g. Vp3), which are not expressed in the BALB/c mouse, were 
below 0.1% (data not shown), and the background expression of Vp 8.1 in tetramer 
negative CD8^ T cells did not increase significantly over time. Thus we have shown a 
restriction of TCR Vp chain usage amongst the tetramer positive population, which 
parallels the continuous accumulation of antigen-specific T cells during viral latency.
4.1.3.3. Phenotype o f pp89-speciflc T cells early and late after infection with MCMV and 
Vac89
The phenotype of pp89-specific CD8^ T cells was analysed early and late after infection
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with MCMV and Vac89. A panel of phenotypic markers was used to assess the 
activation and maturation state of pp89-specific CD8^ T cells. Ten days after MCMV- 
infection, pp89-specific T cells showed an activated phenotype in the spleen (mainly 
and CD62L^°) Only 9% of pp89-specific CD8^ T cells were positive for the 
early activation marker CD69 and the percentage of CD25^' CD8^ T cells was negligible 
(Fig. 3). The vast majority expressed the proinflammatory adhesion molecules CD44 and 
CD18.
Six days after infection with Vac89, specific CD8^ T cells showed slightly lower 
expression levels of CD43*®^  ^ and CD69, while the expression level of CD44, CD 18 and 
CD62L was comparable to those after MCMV-infection. During the memory phase 
MCMV- and Vac89-infection, pp89-specific CD8^ T cells were CD43^®"’^‘’ , CD44^‘ 
and CD18^\ However, there was a clear difference in the expression of CD62L: the 
majority of pp89-specific CD8^ T cells remained CD62L*° late after MCMV-infection 
whereas after Vac89 infection, only a minority were CD62L*°. In addition, as late as 400 
days after MCMV-infection, a distinct population (11%) of pp89-specific cells expressed 
CD69 -  slightly more than during acute infection.
We went on to analyse CD69 expression on tetramer positive CD8^ T cells in different 
organs. Strikingly, while moderate amounts of CD69^' pp89-specific T cells could be 
seen in the spleen, blood, liver and lung, the frequency was significantly higher in the 
lymph nodes, often reaching 30% (Fig 4A). This pattern was reproducible across lymph 
nodes from the mesenteric, cervical and axillary groups. As controls, tetramer negative 
CD8^ T cells from lymph nodes in MCMV and Vac89 infected mice and naïve mice all 
showed much lower levels of CD69 expression (% CD69^' < 10%, data not shown). The
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relationship between the cells in the different compartments and the kinetics of 
activation are complex (203), but a reasonable conclusion from these experiments would 
be that antigen specific activation of pp89 specific CD8^ T cells is occurring within the 
LN throughout MCMV-latency.
4.1.3.4. Proliferation o f pp89-specific memory CD8^ T cells late after MCMV-infection 
To examine the proliferation of tetramer positive CD8^ T lymphocytes in vivo, we 
performed BrDU labelling experiments. After 10 days of labelling, the incorporation of 
BrDU into tetramer positive and tetramer negative CD8"'’ T lymphocytes was analysed in 
MCMV-infected mice. An example of such an experiment is shown in Fig. 4B. As 
expected, a very high proportion of tetramer positive cells have incorporated BrDU 
during the acute phase of infection (about 90%). The rate of incorporation of BrDU in 
tetramer positive cells during the latent or memory phase -  250 days later - was 
approximately one fifth of this. A small but consistent difference in the incorporation of 
BrDU into tetramer positive cells and total CD8^ T cells was seen (mean 16.7% v 
12.7%), as has been noted in similar experiments after infection with murine gamma 
herpesvirus-68, where similar incorporation rates were obtained (204). The lower 
frequencies of pp89-specific cells late after Vac89 infection limit the information that 
can be obtained from such analyses during the memory phase. Overall therefore the rate 
of proliferation of tetramer positive cells as judged using this assay was sustained during 
MCMV-latency at a level substantially lower than that seen acutely but on a par with 
other persistent infections.
4.1.3.5. Long-term accumulation o f memory cells is not uniform and is not restricted to
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pp89-specific CD8^ T cells
To evaluate whether accumulation of MCMV-specific CD8^ T cells was restricted to the 
IEl/pp89-specific response, we measured specific CD8^ T cell frequencies for epitopes 
derived from 5 different viral proteins up to 200 days after MCMV-infection. Of these, 
only pp89 is generated during the lE-phase of MCMV-replication (37). gp34 (m04), p65 
(M84) and probably the ml 64 gene product are expressed during the E-phase and the 
structural virion protein ppl05 (M83) is expressed during the L-phase (26,27,195,196). 
The MCMV-specific CD8^ T cell-response, as measured by intracellular cytokine 
staining for IFNy was clearly dominated by pp89-specific and ml 64-specific cells during 
productive infection and particularly during latency. Ten days after infection, 3-4% of 
CD8^ T cells were specific for pp89 and m l64 derived epitopes (Fig. 5A), while only 
0.2-0.5% were specific for the other three epitopes (Fig. 5B). Thereafter, CD8^ T cell- 
responses for subdominant epitopes all declined to 0.07% (close to the limit of detection 
of the assay) and were maintained at such low levels without evidence for accumulation. 
This was in stark contrast to pp89- and ml 64-specific cells, which increased in 
frequency over the period of latency (Fig. 1, 5A&B; Table 1).
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4.1.4. Discussion
CMV is a major pathogen, which infects most of the world’s population. It causes little 
disease normally because it is well controlled by the host’s immune system. A number of 
mechanisms are important but a key element is the CD8'*' T lymphocyte response. 
However if these mechanisms fail, as a result of immunosuppression (e.g. during AIDS 
or after transplantation), the disease caused by CMV is very significant. Similarly, it is 
also a significant disease causing pathogen in the foetus and newborn. Understanding the 
immune response against CMV is of relevance for two main reasons: firstly because of 
its pathogenic potential and secondly because immune mechanisms are responsible for 
life long control of persistent CMV-infection. Emerging data suggest that in CMV- 
seropositive healthy individuals, a significant effort is expended daily in simply 
suppressing CMV reactivation (205,206).
Of all the CD8^ T cell-responses against human virus infections uncovered with recently 
developed technologies, those against herpesviruses like EBV and CMV are by far the 
largest in fi*equency (115). After acute EBV-infection massive CD8^ T cell responses 
directed against lytic viral epitopes are culled substantially with resolution of lytic 
infection, while other responses become more prominent during latent infection (122, 
127, 180, 207). Since acute HCMV-infection is usually clinically silent, very little is 
known about how antiviral CD8^ T cells evolve from primary infection into the large 
populations often seen in asymptomatic seropositive individuals (up to 10% of CD8^ T 
cells), particularly in the elderly (23, 87, 202, 208-210). This observation prompts the 
immediate question of how such responses emerge and what their evolution is in the 
long term. We have addressed these questions using the murine model of CMV-
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infection. This allowed us to experimentally address the mechanisms behind the 
development of such populations and the factors behind their maintenance.
Most strikingly, after initial expansion and contraction phases the frequency of CD8^ T 
cells specific for some MCMV-derived epitopes continues to increase long after the 
resolution of primary infection. This accumulation -  which we have termed memory 
“inflation”- was not uniform. CD8^ T cells specific for IEl/pp89 and for m l64 clearly 
showed this phenomenon, but frequencies of cells specific for other viral epitopes did 
not increase. Enrichment of pp89- and ml 64-specific but not m04-, M83- and M84- 
specific CD62^° effector memory CD8^ T cells in the latent phase of MCMV-infection 
has been recently observed and a role of these cells in control of viral latency was 
proposed (196, 211). In these studies, a model of MCMV-induced interstitial pneumonia 
after immunosuppression by irradiation with subsequent hematopoietic reconstitution 
with syngeneic bone marrow was used. By homeostatic proliferation of cells in the 
lymphopénie host, this procedure has the potential, to induce alterations of magnitude, 
fimction and phenotype of these CD8^ T cell-responses, which are not directly related to 
the virus-host interaction (212-214). However, our results confirm and extend these 
findings to a more natural situation of MCMV-infection of immunocompetent mice and 
provide a longitudinal analysis of the kinetics of virus specific CD8^ T cells.
Both epitopes, which showed an increase in population size over time, are already 
dominant in acute disease, but the pattern of CD8^ T cell accumulation is not restricted 
to lE-proteins nor to specific MHC class I molecules. From the experiments presented 
here we cannot conclude that immunodominance during early productive infection is 
necessary for later accumulation, since other factors within the virus-host balance might 
influence the long term kinetics of the CD8^ T cell response considerably. The initial
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infectious dose used, although relatively high in this study, was not important in 
determining the later accumulation of cells, as similar results were obtained using 
infectious doses three orders of magnitude lower (Fig. 6A).
One reasonable explanation for the accumulation of IEl/pp89 specific CD8^ T cells 
would be, that this protein is expressed very early during the viral life cycle. Thus, 
expression of pp89 during viral reactivation events is more likely to occur than for 
proteins derived from genes with E- and L-expression kinetics. Indeed, mRNA for 
IEI/pp89 and IE2 has been found during MCMV-latency, but usually transcription does 
not proceed to those E- and L-genes studied to date, unless MCMV-reactivation is 
promoted by immunosuppression or allogeneic transplantation (8-11, 215). Thus, IE I 
specific CD8^ T lymphocytes active in such a site might provide an early ‘checkpoint’ 
preventing progression of the virus to full reactivation. In addition, presentation of IE- 
derived CD8^ T cell-epitopes by macrophages, which are an important source of latent 
virus (216), is efficient despite MHC class I downregulation by MCMV, which strongly 
interferes with presentation in general of E- and L-derived CD8  ^ T cell-epitopes (38, 
217).
M164 is not expressed under the same promoter as IEl/pp89, and its biological function 
is not yet clear. Although it is probably expressed during the E-phase, the epitope is 
efficiently presented despite MCMV-interference with MHC class I presentation (218). 
Whether this then provides a second ‘checkpoint’ is currently a matter of speculation. 
However, the crucial role of CD8^ T cells in the overall maintenance of MCMV-latency 
and prevention of reactivation has been clearly established, since combined depletion of 
critical immunological mediators (B cells, NK cells, CD8^ and CD4^ T cells), viral
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recrudescence is extremely rapid (68). Accumulation of CMV-specific CD8^ T cells may 
therefore arise from the unique biology of CMV, where a large depot of virus exists in 
multiple sites, which is readily reactivated and which demands a rapid response from 
‘effector’ memory T cells.
These patterns -  inflationary responses to some epitopes but not others - may well be 
mirrored in HCMV, although there are important differences. Seropositive individuals 
often have persistently high frequencies of HCMV-specific CD8^ T cells with a narrow 
clonality suggesting antigen driven expansion (22, 202). These responses are readily 
detected against the HCMV-tegument protein UL83/pp65 -  a response, which has no 
apparent parallel in MCMV. As shown in Fig. 5C, the positional and functional MCMV- 
homologues of UL83/pp65, namely M83/ppl05 and M84/p65, elicit only weak CD8  ^T 
cell responses without evidence for accumulation. More recently, strong CD8^ T cell- 
responses specific for HCMV IE1/UL123, the human equivalent of pp89, have been 
described suggesting a co-immunodominance for pp65 and lEl (24, 25, 86, 210,219). It 
has also been shown that MHC class I loading by UL83/pp65-derived peptides occurs 
efficiently by an alternative pathway (cross-presentation), before interference with 
antigen presentation by HCMV is fully operational (20). To our knowledge, no 
systematic study has described the long-term evolution of HCMV-specific CD8^ T 
lymphocyte responses, and their relative specificity, but our findings suggest that such a 
specific study would be of considerable interest.
Accumulation of pp89-specific CD8^ T cells was only observed when mice were 
infected with MCMV and not after infection with Vac89, indicating a crucial role of the
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viral biology in driving these accumulating populations. Multiple patterns of ‘memory’ 
kinetics have been studied in murine systems, and to date these have roughly fallen into 
two patterns. Several viruses show large initial expansions followed by contractions, 
with a stable memory pool (the "burst size model'), where the initial expansion of specific 
cells is followed by 90-95% contraction to stable memory T cell frequencies. Thus, the 
level of memory is determined by the peak of the acute response (120, 125). Vac89, 
which does not persist, may well follow such a pattern. On the other hand, for persistent 
infections this concept has already been adapted, since the frequency of memory CD8^ T 
cells stabilizes at higher levels than anticipated by the ‘burst size model’ (126). 
However, in none of the cases studied to date has this ‘inflationary’ pattern been 
observed, so this might represent yet another potential pattern for viruses where 
persistence is an important part of their biology.
The issue of different patterns is raised after infection with EBV, another persistent 
herpesvirus, where there seem to be at least two different sets of CD8^ T cell-responses 
(127, 180, 207). Frequencies of cells specific for lytic viral proteins usually showed the 
kinetic of a 'burst size response', with rapid but rather asymmetric contraction after the 
initial expansion. In contrast, the frequency of T cells specific for latent viral proteins 
was less dominant during acute infection and sometimes gradually increased, dominating 
the EBV-specific memory pool. Although some evidence is accumulating for 
programmed contraction of CD8^ T cell-pools after infection (220), in some situations 
where virus persists and where it represents a continuous threat to the host, this 
contraction may be less apparent for the total pool of epitope specific T cells. While 
some clones might be in contraction, others might re-expand due to re-encounter of
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persisting antigen. Thus the exact viral biology becomes crucial in determining the shape 
of the immune response in vivo.
We have addressed additional questions about the mechanism behind this phenomenon. 
During primary infection with MCMV, pp89-specifrc T cells have an activated 
phenotype (Fig. 3), which is comparable to Vac89 infection. However, late after 
infection (day 100-400), there was a clear difference in CD62L-expression: > 80% of 
pp89-specifrc CD8^ T cells were CD62L^° after persistent MCMV-infection but CD62L^' 
after transient Vac89-infection. In mice, antigen-persistence has been correlated with 
long term maintenance of CD62L^° 'effector' memory cells (221) and their preferential 
localization outside of lymphoid tissue (222). More recently protection against bacterial 
challenge with Listeria monocytogenes was shown to be mediated exclusively by 
CD62L^° CD8^ T cells (223). However, ex vivo we did not find a significant functional 
difference in IFNy production and cytotoxicity (not shown) between pp89-specific 
CD62L^° effector memory cells after MCMV -infection and CD62L^' 'central' memory 
cells after Vac89-infection. Nevertheless, the finding of accumulating ‘effector’ memory 
cells capable of patrolling solid organs like lung, liver and salivary gland supports the 
concept that latent virus is constantly initiating reactivation which is prevented by 
circulating MCMV-specific CD8^ ‘effector’ memory cells.
Consistent with this phenotype, we observed a striking activation of pp89-specific CD8^ 
T cells during viral latency. This was most marked within lymph nodes, where, as in 
other infectious model systems, the frequency of tetramer positive cells is rather low 
after iv infection compared to other secondary lymphoid organs (222). Remarkably, 
nearly one third of pp89-specific cells showed signs of recent activation one year after
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infection (Fig. 4A). Prolonged maintenance of CD69^‘ CD8^ T cells particularly within 
draining lymph nodes has also been observed after infection with Influenza A virus, 
which does not establish a persistent infection, although very late time points have not 
been similarly studied (203). It is likely that the localization of CD69 MCMV-specific 
cells is related to the distribution of peptide-loaded antigen presenting cells (APC), 
which may be concentrated in lymph nodes. In experiments with HCMV, cross 
presentation of lEl derived epitopes by dendritic cells has been observed, so the 
localization of APC and virus infected cells may be distinct (224).
The fate of CMV-specific CD8^ T cells is not yet clear as some may divide and many 
may disperse into tissues thereafter or potentially die in situ. The data from the BrDU 
experiments gives some indication of the rate of proliferation of the pool, which appears 
marginally higher than that of tetramer negative cells. Although this assessment cannot 
account for redistribution of cells and death in tissues it does indicate that a difference 
exists between proliferation rates of the pp89 specific cells and other heterogeneous 
CD8^ T cells. Even if this difference is small it could account on its own for the slow 
accumulation seen after MCMV infection. A difference in proliferation rate of 0.03% per 
day, over a 200-day period, would account for a relative doubling in size of the tetramer 
positive population in comparison to the rest of the CD8^ T cell pool. Although a similar 
picture of proliferation amongst tetramer positive and total CD8^ T cells has been 
described after infection with persistent MHV-68, no such accumulation of tetramer 
positive cells has been documented (204). Further analysis of the rate and site of death of 
specific cells across the entire organism is therefore required to understand the gradual 
accumulation, which appears unique to this system. Also, even longer experiments will
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be required to assess the long-term fate of these populations over the lifetime of the 
animal.
Recent reports on the phenotype of human CDS'*' T cells after infection with several 
persistent viruses revealed a substantial heterogeneity dependent on the infecting agent, 
the time after infection and the particular epitope studied (127, 160, 225). In addition, 
they are also heterogeneous between individuals. The experiments shown here represent 
a controlled attempt to understand one particular outcome of a host-virus interaction but 
one which is still clearly relevant to man, as strongly emphasized by recent reports (226). 
The specific phenotype of CDS'*’ T cells is likely to be dependent on the individual and 
possibly unique biology of different viruses and their respective hosts. Nevertheless, the 
MCMV-specific CDS'*’ T cell responses described in this report followed unique kinetics 
during latency, which are unprecedented. These results are highly relevant to persistent 
human infections and present a potential new paradigm for understanding certain 
specific host-virus or host-vaccine relationships. Since infection with HCMV is 
widespread, understanding this phenomenon has potentially significant implications for 
the development over time of the ‘normal’ human immune system.
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4.2. Chapter 2
Sustained expansion of CD8  ^ T cell responses driven by recombinant 
cytomegaloviruses
4.2.1. Summary
CD8^ T cells are critical for the control of many persistent viral infections such as HIV, 
HCV, EBV and cytomegalovirus (CMV). In most infections large CD8^ T cell 
populations are induced early but then contract and are maintained thereafter at lower 
levels. In contrast, CD8^ T cells specific for mouse (M) CMV have been recently shown 
to continue to accumulate after resolution of primary infection. This unique behaviour 
was restricted to certain epitopes, including an immunodominant epitope derived from 
the Immediate Early 1 (lEl) gene product. To explore the mechanism behind this further 
we measured CD8^ T cell-mediated immunity induced by recombinant MCMV 
expressing epitopes derived from influenza A virus or LCMV, placed under the control 
of an IE promoter. We observed that virus-specific CD8^ T cell populations were 
induced and that these expanded gradually over time. Importantly, these CD8^ T cells 
provided long-term protection against challenge without boosting. These results 
demonstrate a unique pattern of accumulating T cells, which provide increasing immune 
protection over time, independent of the initial immunodominance of the epitope, and 
indicate the potential of T cell-inducing vaccines based on persistent ‘self-boosting’ 
vectors.
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4.2.2. Introduction
CDS'*’ T lymphocytes play a critical role in the control of persistent infections such as 
mV, Hepatitis C virus (HCV), EBV and cytomegalovirus (CMV). Defining the nature of 
CDS'*’ T cells mediating immunological protection and the rules governing the 
maintenance of these cells is crucial not only for our understanding of the pathogenesis 
of such infections but also for the design of T cell-based vaccines. It is clear that memory 
T cell populations may persist in the absence of antigen or further triggering of their 
TCR (227-229). However, it is also clear that the biology of the inducing pathogen can 
strongly influence the magnitude and the quality of the resulting T cell populations. 
Recent studies using tetramers have revealed that human CD8^ T cell populations 
specific for different pathogens may show considerable heterogeneity in phenotype (127, 
160). In murine models it has been shown that the recirculation pattern, the activation 
status and ultimately the protective capacity of memory T cells may also be influenced 
by the nature of the primary infection (223, 230-232). We have examined in detail the 
unique T cell responses induced by mouse (M) CMV-infection and explored the 
protective capacity of CD8^ T cells generated in response to these pathogens.
We evaluated this issue using recombinant MCMVs. These viruses express foreign 
epitopes derived from influenza A virus or lymphocytic choriomeningitis virus (LCMV) 
under an IE promoter. We tested the hypothesis that such viruses would prime epitope 
specific responses, which would expand during latency, regardless of their initial 
immunodominance, and regardless of the mouse strain used. Additionally we examined 
the protective capacity of these populations in challenge experiments. The data provide 
important insight into the biology of host-CMV interactions and provide a novel 
perspective in the search for T cell based vaccines.
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4.2.3. Results
4.2.3.1. Accumulation ofIEl/pp89-specific CD5^ T cells and association with protection 
against in vivo challenge:
To evaluate the accumulation of MCMV-induced CDS'*’ T cells and its relationship to the 
size of the initial response, BALB/c-mice were infected with low dose (10^) or high dose 
(10  ^PFU) of MCMV i.v. We then measured the frequency of CD8^ T cells specific for a 
dominant H2L^-restricted epitope derived from the immediate-early protein 1 (IEl/pp89) 
in blood and spleen by staining with tetramers and we characterised the phenotype and 
fimction of these cells longitudinally.
Previously, we have demonstrated that functional pp89-specific CD8^ T cells 
accumulate continuously after high dose MCMV -infection, reaching up to 20% of all 
CD8^ T cells ((233) and Fig. 6A). This accumulation of memory T cells over time is not 
dependent on a large initial CD8^ T cell expansion, since it was also evident after low 
dose MCMV-infection (Fig. 6A and Table 2). In this instance, a much lower initial peak 
of specific CD8^ T cells was generated, but subsequent accumulation during latency 
nevertheless was observed. Between 75-85% of these accumulating pp89-specific CD8^ 
T cells remained CD62L^° after both high and low dose infection in blood and spleen, 
which is characteristic for effector memory cells. More than 90% of pp89-specific cells 
were immediately functional as assessed by ICS (data not shown). The kinetics of 
accumulation in the blood closely reflects the total number of cells within the spleen 
(Table 2) which is similar to our previous observation demonstrating accumulation of 
pp89-specific T cells also in liver, lung, salivary gland and lymph node (233).
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To test the in vivo protective capacity of pp89-specific CD8^ T cells, mice were 
challenged at various time points after MCMV-infection with pp89-expressing Vac89 
(usually 10  ^ PFU), and 4 days later, the W -titre were determined in the ovaries. 
Challenge with recombinant W  has been widely used to test the level of T cell- 
mediated protective immunity in vivo (200, 231, 234-237). The stringency of the assay 
varies with the genetic background of the respective recombinant W , with the dose of 
W-challenge and with the time interval between challenge and analysis.
Mice were completely protected against Vac8 9-challenge from day 10 until day 272 after 
infection with a high dose of MCMV (10  ^PFU, Fig. 6B). We observed no protection 
after challenge with an unrelated W  at any time point after priming, indicating that 
protection was pp89-specifrc and was not significantly influenced by natural or 
heterologous immunity (not shown). After infection with a low dose of 10^  PFU 
MCMV, no significant protection was observed until day 20. Protection then increased 
until day 75 (when W -titre were 99% lower than in naïve animals) and this level of 
protection was maintained until day 177. Using a lower dose of W  for challenge (10  ^
PFU), 4/4 mice were completely protected against challenge on day 242 (Fig. 6B). 
Overall, for mice primed with 10^  PFU MCMV, the level of protection against challenge 
increased gradually over time after MCMV-infection and thus correlated with increasing 
frequencies of pp89-specific T cells (Table 3).
Protective capacity was associated with a marked expansion of pp89-specific CD8^ T 
cells in vivo after W  infection. These expansions were antigen-specific, they occurred 
in spleen (Fig. 6C), blood, liver, lymph node and ovaries (data not shown) and they 
showed a positive correlation with the in vivo protective capacity. Interestingly, the
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magnitude of the expansion seemed to correlate with the time after MCMV-infection 
(Fig. 6C).
4.23.2. CD8^ T cell-induction by recombinant MCMV
To test the potential of MCMV to induce CD8^ T cell responses against recombinant IE- 
expressed epitopes and to evaluate whether memory inflation would also occur in a 
different genetic background of the host, we generated two different recombinant viruses 
encoding two H2-D^-restricted murine CD8^ T cell-epitopes. They were derived from 
Influenza A virus nucleoprotein (NP366-374, MCMV-NP) and from lymphocytic 
choriomeningitis virus (LCMV) glycoprotein (GP33-41, MCMV-GP) and included two 
additional N- and C-terminal flanking amino acids. Recombinant epitopes were 
introduced into MCMV-IE2, which is dispensable for in vitro and in vivo viral 
replication, and is expressed before MHC class I interference by MCMV becomes 
operational during the early (E) phase of viral replication (2, 38). In addition, IE2- 
transcripts have been found during MCMV-latency (10).
Mouse embryonic fibroblasts (MEF) infected with MCMV-NP and MCMV-GP 
expressed IE2 similar to wild type (wt) virus, when transcription and translation of viral 
lE-proteins were synchronised with metabolic inhibitors. As expected, the IE2-protein of 
the recombinant viruses was slightly larger than of MCMV-wt due to the inserts (Fig. 
7A). Replication kinetics and cell- and tissue tropism of recombinant viruses was 
comparable to MCMV-wt in vitro and in vivo (not shown).
Ten days after infection of C57BL/6-mice with 2x10^ PFU MCMV-NP or MCMV-GP, 
ex vivo cytotoxic activity was not detectable by ^^Cr-release assay (not shown) and 
tetramer staining was at or below the limit of detection (< 0.15% tetramer positive cells
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of CDS'*' T cells; Fig. 7C, ex vivo). After 5-7 days of in vitro restimulation, cytotoxicity 
specific for recombinant epitopes and staining with the respective tetramer were strongly 
positive (Fig. 7B and 7C, restim.). These results demonstrate that priming of CD 8  ^T 
cells specific for recombinant epitopes expressed in MCMV-IE2 did occur early after 
infection, but the responses induced were initially of low magnitude.
4.2.3.3. Slow accumulation o f NP-speciflc CD8^ T cells after infection with MCMV-NP 
and correlation with protective immunity
We next analysed NP-specific CD8^ T cells emerging over time after infection with 
influenza or MCMV-NP (238). We used several phenotypic markers to analyse 
activation status and presumable recirculation pattern of NP-specific CD8^ T cells. In 
particular CD62L-expression was used to differentiate between 'central' memory CD8^ T 
cells (CD62L^') and effector memory cells (CD62L^°) (221, 223, 233, 239). We 
compared the responses generated after persistent infection with recombinant MCMV 
with those elicited by the same epitope after natural, acute and transient influenza 
infection.
After influenza infection, NP-specific CD8^ T cells rapidly expanded reaching a peak of 
4-5% of CD8^ T cells after 8-10 days in the blood (Fig. 8A and 9A) and a total number 
of 5.6±2.8 X 10^  cells per spleen (Table 2). More than 95% of the cells were CD18 and 
CD44-positive but CD62L^° and 75-85% produced IFNy ex vivo (Fig. 8B, ICS, CD18 
and CD44 not shown). Early after intranasal influenza infection NP-specific cells in the 
spleen were mostly low in expression of CD69 but high in expression of CD43^® '^ (not 
shown) which is compatible with recent activation (203,240).
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Thereafter, NP-specific CD8^ T cell populations contracted by 90-95% and were 
maintained at a stable memory level of 0.5% of CD8^ T cells in the blood and 3.9-5.2 ± 
2.2 X 10"^  NP-specific cells per spleen (Table 2). As demonstrated previously, within a 
year after influenza infection a substantial proportion of NP-specific CD8^ T cells (40- 
60%) regained expression of CD62L, typical for resting or central memory cells (Fig. 8C 
for day 220; (241)).
After infection with recombinant MCMV-NP a completely different pattern of CD8^ T 
cell-expansion emerged. Up until day 20, the frequency of NP-specific CD8^ T cells was 
generally below or just at the limit of detection by tetramer or ICS reaching 2.5-2.9 ±1.6 
X 10"^  NP-specific cells per spleen (Table 1, Fig. 8A & 9A, ICS not shown). If NP- 
specific cells were measurable by tetramer staining early after MCMV-infection (and not 
below the limit of detection), they expressed high levels of CD 18 and CD44 but they 
were consistently low in CD69, CD43^ ®^  ^ and CD62L suggesting previous contact with 
antigen but a lower level of activation than after influenza infection (not shown and Fig. 
8B).
Slowly but steadily, frequencies of NP-specific T cells increased over time, reaching a 
level of 1.5% of CD8"^  T cells by day 120 (12.7±4.8 x 10"^  cells/spleen). Thereafter, we 
observed no further increase but rather fluctuating T cell frequencies ranging between 
0.7-1.8% (9.15±5.3 X 10"^  cells/spleen). In the memory phase, 85-90% of NP-specific 
CD8^ T cells maintained a CD62L^° effector memory phenotype (Fig. 8B for day 220) 
and produced IFNy ex vivo (ICS not shown).
To compare the level of protection generated after infection with influenza with that 
generated after MCMV-NP infection, mice were challenged at different time points with
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5x10^ PFU VacNP i.p. Four days later, we measured the VacNP-titre in the ovaries. 
These three viruses only share one single CTL-epitope (NP366-374).
As expected from the frequency of functional NP-specific T cells, mice were highly 
protected against VacNP-challenge during the first 50 days after influenza infection (Fig. 
9B, upper panel). Thereafter, protection was partially and gradually lost in parallel to the 
loss of NP-specific memory cells resulting, as expected, in a negative correlation 
between the time after influenza infection (priming) and the level of protection of c = - 
0.736 (p<0.001. Table 3). However, on average, VacNP-titres were still 96% reduced 
compared to naïve mice 430 days after influenza infection.
In contrast, over the first 35 days, mice infected with MCMV-NP were not protected 
against VacNP-challenge. Only by day 50, when NP-specific CDS’*" T cells had 
accumulated sufficiently, a significant level of protection (99.97%) was reached, 
comparable to mice infected with Flu (Fig. 9B, lower panel). A high level of protection 
was maintained thereafter, correlating roughly with the frequency of NP-specific CDS'*’ T 
cells (c=0.507, p=0.014), although there was considerable variation between individual 
mice late after priming. Nevertheless, the level of protection was positively correlated 
with the time since priming with MCMV-NP (c=0.513,p=0.012, Table 3).
4.2.3.4. Protective CD8^ Tcell-mediated immunity after infection with MCMV-GP 
We used the same system to analyse immunity generated against a second antigen, in 
this case derived from LCMV. We compared the GP-specific CD8^ T cell-response after 
infection with MCMV-GP, after infection with W  recombinant for LCMV-GP (VacGP) 
and after immunization with GP33-41 peptide emulsified in CFA (Fig. lOA). The
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response generated by VacGP was maximal on day 6 and then dropped to a stable 
memory level of 0.4% of CD8^ T cells. After immunization with GP33 in CFA, GP- 
specific T cells expanded to 1.9% within 10 days and were then maintained at a nearly 
constant level for 120 days reflecting the granulomatous inflammation and delayed 
antigen release provoked by CFA. However, total numbers of GP-specific cells per 
spleen dropped from 25±9.7 x 10"^  on day 10 to 10.9±2.6 x lO'^  on day 120 (Table 2). In 
contrast, after infection with MCMV-GP, GP-specific CD8^ T cells also showed the 
pattern of ‘memory inflation’ as demonstrated previously for NP-specific T cells after 
infection with MCMV-NP. By day 120, about 1.3% of CD8^ T cells were GP-specific in 
the spleen. Overall, the total number of GP-specific cells per spleen increased from 
l.I±0.5 X 10"* on day 10 to 15.5±2.3 x 10"^  on day 120 (Table 2).
Mice infected previously with MCMV-GP or immunized with GP33+CFA were then 
challenged with VacGP, and W -titre was measured in the ovaries. GP33+CFA induced 
partial protection from 10 day until day 65 of about 99% compared to naïve mice. By 
day 250 however, protection was lost completely (Fig. lOB, upper panel). In contrast, 
protection generated by infection with MCMV-GP developed more slowly within 40 
days (99.7%), but was then maintained with considerable variation between individual 
mice (Fig. lOB, lower panel).
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4.2.4. Discussion
In this study we have demonstrated that the pattern of continuously accumulating CD8^ 
T cell responses after CMV-infection is neither restricted to certain T cell epitopes nor to 
a particular strain of inbred mice. Accumulation was observed for immimodominant and 
for subdominant epitopes, it was independent of the dose of infection and even T cells 
specific for recombinant epitopes accumulate over time. These T cells are of the effector 
memory phenotype and provide -  as they accumulate - long term protective immunity. 
These findings have important implications for our understanding of the immunological 
long-term control of CMV infection in mouse and, potentially, humans. In addition, they 
provide a first proof of principle for the use of persisting vectors to maintain or even 
increase protective CD8^ T cell responses without external antigen re-exposure.
Efficient induction of protective CD8^ T cell-responses by crosspriming with non­
replicating antigens has proven to be a difficult task to achieve despite constant 
refinement of vectors and immunization protocols and despite recent improvements of 
our understanding how innate immune mechanisms direct and enhance the adaptive 
immune response (242). It is even more challenging to develop practical immunization 
regimes capable of maintaining T cell-mediated protection over prolonged periods of 
time, and it has been suggested that persistent antigen is required (231, 236). Our results 
support and extend these findings: CD8^ T cell-mediated protection against challenge 
with recombinant W  decreased late after infection with live influenza. Loss of 
protection correlated with the decreasing frequency of memory T cells and particularly 
within the subset of effector memory cells. This was despite a very potent primary CD8^ 
T cell-response, which was quantitatively at least 30-fold higher after influenza infection 
compared to infection with MCMV-NP (NP-specific CD8^ T cells/spleen on day 8:
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7x10^ vs. < 2x10^ )^. Similarly, protective immunity was lost late after priming with 
synthetic GP33-peptide, despite the use of a very potent adjuvant, inducing inflammation 
and slow antigen-release (243). In addition, protection against challenge with LCMV is 
known to decrease within 80 days after priming with recombinant W  expressing 
LCMV-GP (231, 236)). These different priming conditions, although very efficient 
initially, share the feature of transient antigen delivery to CD8^ T cells. Conversely, 
protective immunity increased over time after priming with recombinant MCMV. This 
correlated with accumulation of epitope-specific effector memory T cells.
The cells generated by MCMV infection have the characteristics of ‘effector’ memory T 
cells, possessing rapid effector fimction ex vivo and more importantly, providing 
protection in vivo. The phenotype shown is probably similar to the ‘mature’ memory 
phenotype associated with HCMV-specific T cell populations in man (87, 160, 210). 
These cells remain low in CD62L and may therefore effectively patrol and protect 
nonlymphoid organs. Indeed, in addition to accumulation in blood and spleen as 
demonstrated here, accumulation of memory T cells in other organs (liver, salivary 
gland, lung, ovary etc) has been recently demonstrated in BALB/c mice (233). Similarly, 
after challenge with recombinant W , very striking expansion of virus specific CD8^ T 
cells occur rapidly in the spleen (Fig. 6C) and in the liver (up to 40% of infiltrating CD8^ 
T cells; not shown). Furthermore, these CD8^ T cells were efficient to protect from W  
replication in the ovaries. It has been demonstrated that the protective capacity of an 
mii-Listeria monocytogenes response induced by vaccination, is strongly linked to 
CD62L expression and thus to the recruitment and redistribution characteristics of CD8^ 
T cells (223). Recent data has, however, suggested that in other situations the protective
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capacity of central memory T cells generated from TCR-transgenic mice is even more 
significant compared to effector memory cells, and this has been linked to an increased 
proliferative capacity of central memory cells (237). Although the CD8^ T cell- 
populations after MCMV-infection (pp89-, NP- and GP-specific) were not pure, they are 
largely effector memory (>75%) and nevertheless did show strong protective capacity 
(Fig. 6B, 9B & lOB) and massive expansion upon challenge (Fig. 6C), suggesting that 
these experiments may depend on the exact nature of the priming and its duration, and 
the exact nature of the challenge.
Although formal experimental proof is lacking, a reasonable explanation for this unique 
pattern of accumulating CD8^ T cells, mediating increasing long-term protection, is 
persistent exposure to antigen. This is supported by recent virologie studies in MCMV: 
transcription of lEl and IE2 (the gene loci, where the recombinant epitopes were 
inserted) occurs randomly during MCMV-latency and the frequency of these events 
seems to depend on the amount of latent MCMV-genomes (8, 10, 244). These are the 
first steps of any reactivation event of MCMV. Whether or not the reactivation proceeds 
fiirther to transcription of early and late genes is likely to be under immune control and 
does usually not occur. CD8^ T cells have been shown to be most crucial to maintain 
MCMV-latency (68). Therefore, CD8^ T cells specific for lE l- and IE2-derived epitopes 
will encounter their cognate antigen repetitively by early reactivation events in MCMV- 
latency leading to endogenous boosting. Moreover, MCMV-dependent MHC class I 
downregulation is not yet operational during the lE-phase of viral reactivation attempts, 
contributing to efficient presentation of these epitopes (38). Interestingly, we and others 
have found similar accumulations of CD8^ T cells specific for an epitope derived from
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m l64, which is not expressed under the IE promoter (Fig. 5B and (196, 218)). It is 
possible that recombinant epitopes inserted in this and potentially other gene loci may 
show similar patterns of immunogenicity.
Clearly, we have not used specifically developed vaccine vectors, adjuvants or 
sophisticated immunisation regimes in our control groups, which would certainly 
improve the efficiency of CD8'*’ T cell-induction. Nevertheless, we have used the original 
pathogen (influenza) in a major part of this study and most modem vaccines are still less 
efficient to induce immune responses than the natural pathogens (245). However, we 
have not selected the recombinant MCMV for high expression of recombinant epitopes 
in vivo, for their optimal processing or for expression of additional immunostimulatory 
effects and we have used a similar straightforward immunisation protocol for 
recombinant MCMV. Additionally, our recombinant vimses still express the whole 
'machinery* of immune deviation and subversion, particularly concerning MHC class I 
fimction (38, 246). It seems quite likely that deletion of some of these genes might lead 
to an attenuated viral phenotype while increasing immunogenicity, since the induction of 
an antiviral immune response becomes more potent without immune deviation. This has 
indeed been demonstrated recently for an MCMV deletion mutant of m l52, an MCMV- 
E-gene responsible for retention of MHC class I peptide complexes in the cis-Golgi 
compartment (247). It will therefore be important to demonstrate whether attenuated 
MCMVs retain the characteristics of protective memory T cell accumulation described 
in this study.
72
MCMV as a model for persistent viral infection PhD-Thesis by U. Karrer
In relation to man, recent studies have shown that very large numbers of functional 
HCMV-specific CD8^ T cells are present in seropositive individuals long after resolution 
of primary infection (23, 87, 202, 208, 210). In the elderly such responses comprise a 
significant proportion of the total lymphocyte pool (209, 248). In addition, certain 
activation markers such as CD69 are over-represented in HCMV-specific CD8^ T cells 
suggesting recent encounter of antigen (249). However, since primary infection is 
usually clinically silent, we know little about the longitudinal evolution of these massive 
HCMV-specific CD8^ T cell-pools over time. Clearly, further studies are needed to 
evaluate whether the principle of ,memory inflation' in mice also applies to certain 
HCMV-specific T cell responses in humans.
The most likely explanation for these massive HCMV-specific T cell populations in 
healthy seropositive individuals is, that HCMV like MCMV constantly initiates 
reactivation during clinically latent infection (8, 10). This leads to a repetitive (or 
possibly constant) triggering of HCMV-specific memory T cells, which both prevent 
reactivation and lead to accumulation of T cells over time. Whether memory inflation is 
needed to maintain virologie control or whether a stable level of memory T cells would 
perform the same function, remains speculative. Addressing this question requires veiy 
detailed analysis of the extremely low viral load of MCMV or HCMV and its 
distribution over time.
The pattern of CD8^ T cell responses demonstrated here is unique. To exploit this type 
of immune response for the development of a safe vaccine, a persistent CMV-based 
vector would have to be engineered to allow latent infection with regulated recombinant 
protein expression without the possibility of productive reactivation. Vaccines based on
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life attenuated herpesviruses aheady exist in the form of those directed against Varicella 
Zoster virus (VZV, (250, 251)). There, the benefits of protection against disease and the 
risks of reactivation of VZV vaccine strain need to be carefully balanced (252-254). 
Whether we will be able to harness the biology of these viruses to generate safe, 
successful recombinant vaccines for complex infectious diseases like HIV, HCV, 
tuberculosis and malaria, as well as tumours such as melanoma is a challenge for the 
future (255). Additionally, it will be important to establish, in careful long-term 
experiments, whether any of the current DNA-based regimes possess the potential to 
recruit antiviral effector cells over extended periods of time. On the basis of the evidence 
presented here, we would argue, however, that for T cell based approaches, attenuated 
but persisting vectors such as recombinant herpesviruses should be seriously evaluated.
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5. General discussion
5.1. Phenotype and function of T cells in persistent viral infections
Phenotypic analysis of virus- and tumour-specific CD8^ T cells has recently gained a lot 
of attention since the tetramer technology has facilitated ex vivo identification of specific 
T cells and their subsequent analysis by flow cytometry (115). If these phenotypic 
analyses are combined with functional data they can provide previously inaccessible 
information. Without functional ‘upgrade’, the interpretation of the relevance of a 
particular phenotypic profile is very difficult and prone to over-interpretation due to an 
inherently high variability of these biologic parameters, particularly if they are derived 
from small scale and crossectional studies in humans. In addition, if tetramers are used 
to isolate CD8^ T cells for further in vitro analysis, it is important to keep in mind, that 
these reagents can activate CD8^ T cells via their TCR (256). Thus, the phenotype and 
the function of the cells may be altered during isolation compared to the in vivo 
situation.
Several concepts of the longitudinal differentiation of human memory T cells were 
derived mainly from phenotypic analyses of antigen specific T cells by FACS. Based on 
differences in the surface expression of the chemokine receptor CCR7 and the LN 
homing marker CD62L, Lanzavecchia and co-workers proposed to subdivide memory T 
cells into two main populations of ‘central’ and ‘effector’ memory cells. Within this 
framework central memory cells are positive for both CCR7 and CD62L, whereas 
effector memory cells are CCR7- and CD62L-negative (239). Initially, it was also 
postulated that the difference in surface CCR7- and CD62L-expression was linked to an 
important functional difference concerning immediate effector function, measured by ex
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vivo cytokine production, which was restricted to effector memory T cells. This 
functional difference was not confirmed by other studies first in mice and later in 
humans (257,258).
However, the differential expression of CCR7 and CD62L leads to a different 
recirculation pattern of central and effector memory T cells. Central memory cells 
primarily recirculate through and home to secondary lymphoid organs and only become 
activated by re-exposure to antigen, if the antigen is sufficiently drained into the 
lymphoid system. Upon activation central memory cells start to proliferate, differentiate 
into effector cells and migrate to the peripheral (non lymphoid) organs to eliminate the 
antigen. In contrast, effector memory cells inherently patrol through the peripheral sites 
of the body, where they were shown to exert immediate effector function upon antigen 
contact, particularly ex vivo cytotoxicity (222). Therefore, the lag phase between antigen 
contact in the periphery and effector function is potentially much shorter for effector 
memory cells. This has important implications, since immediate control of a peripheral 
infection (which is notable the most natural route of infection) would thus require 
effector memory cells. However, analyses of the protective capacity of effector and 
central memory cells have revealed conflicting results: older studies, which were 
performed before the concept of effector and central memory was established, suggested, 
that protection against peripheral viral challenge was crucially dependent on the presence 
of cells recently activated by antigen (effector or effector memory cells), whereas 
protection against systemic viral challenge was efficiently provided by resting (or 
central) memory cells (231, 236). In Listeria monocytogenes infection, CD8^ T cells 
with a phenotype of central memory cells primed with killed bacteria were inefficient to 
protect against a secondary challenge (223). In contrast, in a different experimental
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setting using LCMV-specific transgenic T cells, protection against challenge infections 
mediated by adoptively transferred central memory cells was superior to effector 
memory cells. This protective effect was linked to the increased proliferative potential of 
central memory cells (237).
Our own experiments suggest that maintenance of substantial populations of effector 
memory T cells after priming with MCMV was clearly associated with protection 
against challenge with recombinant W . Protection was lost preferentially in situations 
where mainly central memory cells were maintained (Fig. 9B & lOB, upper panels). In 
addition, we did not find evidence for a proliferative defect of effector memory cells 
(Fig. 6C). This is supported by a recent study of lung infiltrating T cells during 
respiratory Sendai virus (SV) infection (259). After adoptive transfer of similar numbers 
of SV-specific effector and central memory cells the former proliferated more rapidly 
than the latter and subsequent long-term memory cells were mainly derived fi'om effector 
memory cells. Unfortunately, protection against disease provided by effector as opposed 
to central memory cells was not analysed in this study.
However, in our analysis we did not perform cell separations according to CD62L- 
expression followed by adoptive transfer but we challenged the primed hosts directly. 
Since effector memory and central memory cells coexist at different ratios within the 
primed host, their respective contribution to protection was not assessed separately. 
Therefore, our evidence in favour of a crucial protective role of effector memory cells is 
more indirect than the experiments performed by Wherry et al. who suggest the opposite 
(237).
These studies might have important influences on the potential strategies to induce 
protective T cell memory and on future vaccine design. Based on these results it was
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recently suggested to optimise vaccines according to their ability to induce and maintain 
central memory T cells (260). We think that this conclusion might be premature, since 
the data are derived from a single experimental system mainly using transgenic T cells. 
In addition, as pointed out above, conflicting data on the subject already exist in the 
literature and it is possible, that the outcome of these studies is crucially influenced by 
details of the experimental design including the nature of antigens and adjuvans used, 
the exact timing, dose and route of priming and challenge and the genetic background of 
the animals. The transfer of these data to human vaccine studies is yet a completely 
different issue.
Therefore, further experiments are clearly needed to firmly establish 1) whether the 
model subdividing memory T cells in central and effector memory cells is truly a general 
principle of T cell biology in mice and in humans, 2) whether and how the model applies 
to transient and chronic infections, 3) whether the proliferative and particularly the 
protective capacity of central and effector memory cells are different and 4) what signals 
are needed to preferentially induce and maintain central or effector memory cells.
The last two points might have highly relevant implications for future vaccine design, 
particularly if the presence of one of these cell populations would reflect a correlate of 
protection in an important human disease.
5.2. Protective CD8^ T cell mediated immunity: efficient priming versus continuous 
restimulation
Since many years immunologists debate about how immunological T cell memory is 
best maintained. During the last century the general conception was that memory was 
largely antigen independent. The famous measles outbreak on the remote Faroe islands.
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where protective immunity survived during 65 years between epidemics without 
evidence for sporadic cases, was often cited as a striking example for antigen 
independence of memory (227). However, since measles virus is able to persist in a host 
for prolonged periods of time, this might actually be an example for antigen dependence 
(261, 262). Studies during the early 90ies then suggested that maintenance of T cell 
memory is dependent on persisting antigen (263, 264). This view was again challenged 
first by the demonstration of long term survival of memory cells after adoptive transfer 
into antigen free recipients (265) and later by experiments demonstrating long term 
maintenance of memory CD8^ and CD4^ T cells in an environment deficient of the 
restricting alleles of MHC class I or class n, respectively, excluding restimulation of T 
cells via engagement of their TCR by persisting antigen (228,229,266).
These studies have convincingly shown that memory T cells can be maintained without 
the need for persistent antigen. However, the debate has shifted to the question whether 
maintenance of memory T cells is equivalent to maintaining protective immunity (227, 
267). Some of this controversy is related to the definition of memory: operationally, 
immunological memory is defined by an enhanced reactivity of the immune system to a 
pathogen or antigen that has been previously encountered. This usually reflects the pre­
existence of a clonally expanded population of antigen-specific lymphocytes (268). 
Some would argue that an ongoing low level immune response to a persisting antigen 
would not fall into this definition of memory, since this is not a re-encounter but a 
persistent encounter of antigen (227). Therefore, persistent effector cells and not memory 
cells are responsible for the enhanced immune reactivity. For persistent infections, we 
might use the term infection/immunity, infectious immunity or concomitant immunity, 
as it was suggested by Mackaness more than 30 years ago (269). However, does any
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level of antigen persistence beyond a certain time point after infection disqualify for 
‘true’ memory? What would be the appropriate time point for complete antigen 
elimination? In such a purist concept of memory, adoptive transfer situations only would 
qualify for memory after infection with replication competent organisms, since antigen 
persistence at remote sites of the host or at very low levels is difficult to exclude; 
something we have learned fi'om measles virus infection in man and LCMV-infection in 
mice (165, 261, 262). Clearly, such a narrow definition of memory excluding the 
possibility for antigen persistence does not reflect the natural interactions between 
pathogen and host and has not been selected for during evolution of the immune system. 
Therefore, rules for optimal memory cell persistence developed in experimental systems 
which exclude persistent antigen as a confounding factor should not form the basis for 
vaccine design (270). Nevertheless, these experiments have greatly enhanced our 
understanding of the minimal requirements for memory T cell survival.
Concerning antigen requirements for the maintenance of protective immimity, 
conflicting results have been generated dependent on the exact experimental system and 
the readouts for protection which were used (227, 228, 231, 236, 267, 271). Although 
the research groups of R. Zinkemagel and R. Ahmed both work mainly with the model 
of LCMV-infection to analyse T cell memory, published results seem to support 
opposing concepts: the former maintain the case for a crucial role of persisting antigen 
while the latter provide data for antigen independence of protective CD8^ T cell 
mediated immunity (267, 272). Some of their discrepancies are probably related to subtle 
differences in the experimental design of challenge experiments. The antigens or 
pathogens used for challenge (cytopathogenicity, cell and tissue tropism, replication 
capacity, virulence), the exact route and dose of their administration and the interval
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between challenge infection and tissue sampling may all have a crucial influence on the 
outcome of a protection experiment. In general, the level of previously existing 
protective immunity needs to be higher, both quantitatively in terms of precursor 
frequency and qualitatively in terms of pre-activation status of T cells, for pathogens 
that replicate in the periphery and not within secondary lymphoid organs, 2"  ^ for 
challenge infections administered locally and not systemically and 3"^  ^when the interval 
between challenge and tissue sampling is short (usually less than 5 days) (271, 273). As 
a rough approximation, the stringency of challenge experiments can be evaluated 
according to these rules. The W-challenge measuring protection in the ovaries after 4-5 
days, which we have used here, is thus a rather demanding assay, which needs a high 
level of protective immunity. However, different assays may well depend on particular 
qualities (i.e. pre-activation status) of the prevailing antigen specific cell population: 
peripheral challenges with pathogens that only replicate locally seem to favour 
conditions, where effector T cells or maybe effector memory T cells are present, since 
these cells express adhesion molecules, which are required for peripheral recirculation 
(222, 231, 236, 271). For protection against systemic challenges with pathogens that 
preferentially replicate within secondary lymphoid organs, the recirculation pattern 
might be of little relevance and the proliferative capacity of the pre-existing cell 
population may become more important, particularly if the interval between challenge 
and tissue sampling is rather long (228,237, 265,271).
From the available data it is clear, that central memory cells persist in the absence of 
antigen by homeostatic cytokine driven mechanisms, mainly IL-7 and IL-15 (274-276). 
Reencounter of antigen will lead to a second round of proliferation and effector cell 
differentiation followed by contraction and reversion first to effector memory and later to
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central memory cells (237). However, it seems quite reasonable to speculate that the 
long-term maintenance of effector memory T cells is dependent on persisting or re- 
emerging antigen. Although our results support such a concept, direct experimental 
evidence is lacking.
As a synthesis of these opposing views we would like to propose, that maintenance of 
protective T cell mediated immunity is antigen dependent and probably mediated by 
effector memory cells, if the challenging antigen remains completely outside of 
secondary lymphoid organs. If the challenging antigen rapidly gains access to secondary 
lymphoid organs (i.v. challenge) and time for T cell expansion and differentiation is 
available, protective immunity seems to be antigen independent and efficiently provided 
by central memory cells. However, these experimental situations are two extremes of a 
continuum that rarely occur in nature. Therefore, maintenance of a balanced mixture of 
both memory cell populations is probably warranted for optimal protection. To achieve 
this without fi*equent boosting, persistent antigen is presumably an advantage.
According to another recent concept of T cell differentiation, termed ‘programming’ of T 
cells, an initial brief encounter of specific antigen in the order of 24-72h is sufficient 
stimulation for a naïve CD 8  ^T cell, to divide and differentiate into effector cells and 
subsequently into memory cells, without the need for additional antigen contact (277- 
280). During activation by initial antigen contact, a transcriptional program of the T cell 
is started, which leads to inheritable genetic changes, that drive the cell and her progeny 
along the line effector cell, effector memory cell and finally to the stage of a self 
renewing central memory cell with stem cell like properties (281). It has been postulated 
that even the contraction phase of an immune response is programmed (220). However,
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the quantity and quality of the ensuing effector and memory cell populations depends on 
a variety of exogenous factors during the whole differentiation pathway including 
molecular factors (avidity between TCR and MHC-peptide complexes, density of MHC- 
peptide, duration of their interaction, costimulation, cytokine and chemokine 
envirorunent), cellular factors (nature, origin and activation of APC, CD4^ T cell help) 
and anatomical factors (localisation of initial interaction, i.e. secondary lymphoid organ 
vs. periphery) (281). Overall, full activation of naïve T cells only occurs efficiently in 
secondary lymphoid organs, where these interactions take place in a timely and 
anatomically coordinated fashion (162,282).
It is very fascinating to study ‘programming’ of T cells without the confounding 
influence of further antigen contact and to demonstrate that initial events have such 
profound downstream effects. However, since most of these factors are crucially 
influenced by antigen load, density, distribution and persistence, these models do not 
reflect natural situations. Although it is clear that high level persistence of antigen has a 
detrimental influence on the maintenance and functionality of memory CD8^ T cells 
(168, 283), the tendency to interpret these recent results on ‘programming’ of T cells in 
the sense, that any level of persistent antigen generally has a negative influence on 
immunity (229, 272), is ignorant of a large body of older immunological evidence (267, 
270).
Other recent studies of memory T cell differentiation have identified certain markers 
including expression of the IL-7 receptor (R) a-chain and of CD8aa homodimers on a 
subset of effector cells, that preferentially give rise to long term memory cells, whereas 
the majority of other effector cells undergo apoptosis during the contraction phase of an
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immune response (284, 285). By persistent high level expression of the IL-7Ra these 
cells survive independent of further antigenic stimulation during the memory phase by 
IL-7 and possibly IL-15 driven homeostatic proliferation (274-276).
In addition, several research groups have recently demonstrated the profound influence 
of CD4^ T cells on the development of a robust memory CD8^ T cell response. For many 
years it was speculated, that early help by CD4^ T cells might be crucial for efficient 
CD8^ T cell responses in viral infections with the potential for high level persistence 
(144, 170, 171, 286). Now, more experimental evidence is emerging and potential 
mechanisms have been proposed: an efficient primary response of CD8^ T cells develops 
in the absence of CD4^ T cells but the generation of CD8^ T cell memory is greatly 
impaired mainly by a poor proliferative response to secondary challenge (174-177). It 
remains to be elucidated what the exact mechanism of the interaction between CD4^ and 
CD8^ T cells is and how the important signals are transferred. A direct cognate 
interaction seems to be unlikely, since murine CD8^ T cells do not express MHC class H. 
Conflicting data have been generated, whether the interaction between CD40 (expressed 
on CD8^ T cells) and CD4ÔL (expressed on CD4^ T cells) is crucially involved to 
provide help in this setting, similar to the interaction between B cells and T helper cells 
(174, 287, 288). However, soluble mediators may also be involved but their individual 
contribution has not been evaluated so far.
These studies have important implications both for the understanding of the pathogenesis 
of persistent infections and for rational vaccine design. In persistent infections the role 
and the function of CD4^ T cells needs to be carefully re-assessed together with the 
phenotype and function of the ensuing CD8^ T cell response, particularly during the
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earliest events of primary infection. It will be very difficult to perform such analysis in 
human diseases, but in primary HIV- and EBV-infection such studies might shed light 
on mechanisms of early pathogenesis. In HIV-infection, preferential infection of HIV- 
specific CD4^ T cells has been demonstrated (145) but it is unclear, whether this is 
responsible for a rapid loss of helper activity for CD8^ T cells, which then develop 
fimctional impairment. Different CD 8  ^T cell epitopes could be affected differently and 
it would be interesting to analyse, whether linked T cell help (a CD4^ T cell response 
targeting an epitope derived from the same viral protein) has an influence on the 
fimctionality of CD8^ T cells. In EBV-infection, information could be gathered 
concerning the mechanism behind the massive culling of certain responses, while others 
remain much less affected (127), particularly if a differential expression of IL-7R during 
the expansion phase could be demonstrated. In acute EBV-infection, lack of specific 
CD4^ T cell help seems unlikely but ‘programming’ of contraction will not be accessible 
for analysis in vivo.
In MCMV-infection, we observed clearly less contraction of the CD8^ T cell response 
after primary infection compared to other acute viral infections. It will be extremely 
interesting, to analyse the level of IL-7Ra expression and the proliferative potential of 
MCMV-specific CD8^ T cells longitudinally, particularly if separately analysed for 
effector memory and central memory cells.
In addition, the MCMV-specific CD8^ T cell response in the absence of CD4^ T cells or 
in the absence of CD40/CD40L-interaction needs to be analysed longitudinally, since 
older studies suggest that CD4^ T cells are crucial for complete clearance of productive 
MCMV-replication in salivary glands (96, 97). However, it needs to be re-assessed 
whether this is a direct antiviral effect or whether CD4^ T cells mainly influence other
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effector cells. Moreover, failure of newborns and young children to terminate productive 
HCMV-replication in salivary gland and kidney was associated with a functional defect 
of CD4^ but not CDS'*’ T cells (58, 101). Therefore, these studies of ‘help-deficient’ mice 
need to (re-) address, 1) whether clearance of primary MCMV-infection and 
establishment of latency is clearly impaired, 2) whether the frequency (inflation ?), 
phenotype and function of CD8^ T cells is affected by repetitive or continuous encounter 
of low levels of antigen in the absence of CD4^ T cells and 3) whether strategies could 
be developed to rescue functionally impaired CD8^ T cells in the setting of a persistent 
viral infection (if there is evidence for functional impairment).
For rational design of T cell based vaccines, these studies have profound implications as 
well: the concept of ‘programming’ would suggest that everything is decided during the 
first 24-72 hours. If the initial antigen contact is optimally tuned, then further antigenic 
stimulation is not needed for protective immunity. CD4^ T cells might just be one of the 
factors needed for optimal ‘programming’. However, a most recent study by Sun et al 
contradict this concept (289). They have shown that CD4^ T cells were needed for the 
antigen independent maintenance of memory CD8^ T cells but not for their 
‘programming’. Overall, induction of CD4^ T cells seems to be beneficial for the 
generation of protective immunity mediated by CD 8  ^T cells, but the exact timing and 
mechanisms of help remain poorly defined.
According to the study of Wherry et al, the interval between priming and boosting needs 
to be carefully evaluated to ensure optimal efficacy, since central memory cells only will 
proliferate maximally upon boosting (237). However, these latter results need 
confirmation as outlined previously.
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Probably, truth lies between the extremes of opinions and might in addition be different 
for every individual host-pathogen-situation: neither an initial ‘super-boost’ nor a 
constant low level tickling of antigen will be optimal for protective immunity. The 
optimal regimen for a T cell based vaccine will require a very solid initial priming event 
with optimal T cell help and a careful dosing and timing of boosting possibly by 
different vectors and repetitively. Such a delicate balance between antigen and immune 
system of the host will be difficult to find and additional questions need to be addressed 
concerning epitope targeting (frequency of cells and breadth of a response), use of 
adjuvans or of life attenuated vectors and maybe even use of persistent vectors (267). 
The more we learn about the basic rules regulating the interactions between molecules, 
cells, organs and whole organisms (particularly pathogen an their hosts), the better and 
more rational will be our efforts to generate successful vaccines for diseases, where we 
have failed so far. Our studies on MCMV-infection of mice highlight one possible 
outcome of a particular host-pathogen interaction. We think, that further studies should 
be undertaken to evaluate, whether this specific interaction leading to memory inflation, 
can be used for the benefit of the host.
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6. Figure legends
Figure 1: Accumulation o f pp89-specific CD8^ T cells after infection with MCMV:
(A) MCMV-titre: Mice were infected with 10^  PFU MCMV i.v. and at indicated time 
points MCMV-titres were determined in spleen (filled circles) and salivary gland (open 
circles) by virus plaque assay (lung and liver not shown). MCMV-titres represent 
logio(PFU/organ). Each line represents the mean of 3-4 mice per time point. Error bars 
indicate the standard deviation (SD). Detection limits of the assays: spleen: 1.6 (40 
PFU/organ), salivary gland: 2.0 (100 PFU/organ).
(B) pp89-specijic CD8^ T cells in blood: Mice were infected with 10  ^ PFU MCMV 
(filled diamonds) or 5x10^ PFU Vac89 (filled circles) i.v. At the indicated time points 
blood was taken and PEL were stained with pp89-tetramer and anti-CD8. The 
percentage of CD8^ T cells staining with pp89-tetramer is plotted over time. Each line 
represents the mean of 3-4 mice per experimental group. Error bars indicate the SD 
within experimental groups.
(C and D) pp89-specific CD8^ T cells in the spleen: At indicated time points spleen cells 
were harvested and the fi*equency of pp89-specific T cells was determined by pp89- 
tetramer staining (MCMV: filled diamonds, Vac89: filled circles) and by pp89-IFNy 
(MCMV: open diamonds, Vac89: open circles). In C, the percentage of CD8^ T cells 
positive for pp89-tetramer or pp89-IFNy is plotted over time and in D, the total number 
of pp89-specific CD8^ T cells per spleen is depicted (number x 10^). Each line 
represents the mean of 3-4 mice per experimental group. Error bars indicate the SD 
within an experimental group.
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(E) FACS® dot plots from mice 10 and 400 days after MCMV-infection, from mice 6 
and 300 days after Vac89-infection and from naïve mice. Panels were gated on live 
lymphocytes without B cells (excluded by anti-CD45R-staining). Numbers indicate the 
mean percentage of pp89-tetramer^ or IFNy-producing CD8^ T cells of 3-4 mice per 
group.
Day 300 and day 400 are data from a single experiment of 4 mice per group. Data were 
confirmed by two similar experiments extended until day 250 after infection.
Figure 2: (A) Evolution and distribution o f pp89-speciflc T cells in different organs: 
Balb/c mice were infected with MCMV (1x10^ PFU i.v.). Ten, 40 or 230 days after 
MCMV infection lymphocytes were isolated from different organs and stained with the 
pp89-tetramer and anti-CD8. The percentage of tetramer positive CD8^ T cells is shown 
for each organ. The left panel shows data from lymphoid organs and blood, the right 
panel from non-lymphoid organs. Note the difference in scale. Columns represent the 
mean of 3 mice per group; error bars indicate the SD within an experimental group. One 
out of three similar experiments are shown.
(B) Increasing oligoclonality o f pp89-specific CD8^ T lymphocytes over time:
A panel of TCR Vp reactive antibodies were used to identify VP usage by pp89-specific 
T cells over time in the spleen (day 9, 89, 272 post infection). The columns show the 
percentage of pp89-specific T cells positive for the indicated Vp-family. Vp 8.1-specific 
Abs also detect Vp 8.2 positive cells. 3-4 mice were used per experimental group. Error 
bars indicate the SD within an experimental group. One out of two representative 
experiments are shown.
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Figure 3: Phenotypic characterization o f pp89-specific CD8^ T cells after infection with 
MCMV or Vac89:
Mice were infected with 10^  PFU MCMV, with 5x10^ PFU Vac89 i.v. or left uninfected 
as a naïve control. Spleen cells were harvested at the indicated time points and stained 
with pp89-tetramer, anti-CD8, anti-CD45R and with the indicated phenotypic marker. 
Panels are gated on live CD8^ lymphocytes. Numbers indicate the mean of 3-4 mice per 
group and represent the mean percentage of pp89-tetramer^ CD8^ T cells (row 1-4) or of 
naïve CD8^ T cells (row 5) expressing the respective marker. One out of four (day 6 and 
10) similar experiments are shown. Results from day 300 and day 400 were confirmed 
by two comparable experiments from 160 and 230 days after infection.
Figure 4: (A) CD69 expression by pp89-specific T cell during MCMV latency in 
different organs:
Lymphocytes of mice infected with MCMV 230 days previously were isolated from 
different organs and stained with pp89-tetramer, anti-CD8 and anti-CD69. The 
percentage of pp89-tetramer positive CD8^ T cells expressing CD69 in each organ is 
plotted. Columns represent the mean of 3 mice and error bars indicate the SD. One out 
of two comparable experiments are shown.
(B) In vivo proliferation o f pp89-specific CD8^ T cells after MCMV infection:
MCMV infected mice (day 0 and day 220) were treated with BrdU for 10 days. 
Splenocytes were then isolated and stained with pp89-tetramer, anti-CD8 and anti-BrdU 
antibodies or an isotype control. Panels are gated on CD8^ T cells. Numbers indicate the 
% of tetramer positive cells, which are BrDU positive. Staining with an isotype control 
Ah is shown on the left. In the middle, BrDU-incorporation is shown 10 days after
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infection and on the right 230 after infection. One out of 3 mice are shown. The 
experiment was repeated three times with similar results.
Figure 5: Long-term accumulation o f memory cells is not restricted to pp89-specific 
CD8* T cells:
Balb/c mice were infected with 10® PFU MCMV i.v. Spleen cells were taken at different 
time points thereafter and were tested ex vivo by pep-IFNy. Permeabilised cells were 
stained with anti-IFNy and anti-CD8 antibodies and the mean percentage of IFNy- 
producing CD8^ T cells of 3-4 mice per group is plotted. Error bars indicate the SD 
within an experimental group. The following MCMV-derived peptides fi'om 5 different 
viral proteins were used (MHC class I presenting molecule): pp89 (H2-L‘*), m04/gp34 
(H2-D'*), M84/p65 (H2-K®), M83/ppl05 (H2-L"') and m l64 (H2-D‘‘). (A) Frequency of 
IFNy producing T cells specific for the immunodominant epitopes pp89 and m l64. (B) 
Frequency of IFNy producing T cells specific for subdominant epitopes derived from 
m04, M83 and M84. Note the 10-fold difference in scale between pannel C compared to 
A and B. One out of three comparable experiments are shown.
Figure 6: Protective immunity mediated by pp89-specifîc CD8^ T cells is dependent on 
the dose o f infection and the timing o f challenge:
BALB/c mice were infected with 10  ^ (open diamonds) and 10^  (filled diamonds) PFU 
MCMV i.v. or were left naïve (open circles) as a negative control. Thereafter, the pp89- 
specific CD8^ T cell response was measured longitudinally in the blood (Fig. 6A). The 
percentage of CD8^ T cells staining with pp89-tetramer is plotted over time. Each line
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represents the mean of 4-5 mice per experimental group. Error bars indicate the SD 
within experimental groups.
At indicated time points after MCMV-infection, mice were challenged with Vac89 i.p. 
and the W -titres were measured in the ovaries 4 days later (Fig. 6B). Tiftes are given as 
logio(PFU Vac89/ovaries). The detection limit (det. lim.) and the SD are indicated. Each 
line represents the mean of 4-5 mice per experimental group. One out of two similar 
experiments are shown.
To measure the expansion of specific T cells after challenge the firequency of pp89- 
specific CD8^ T cells was determined by tetramer-staining before and 4 days after 
challenge with Vac89 in the spleen at indicated time points after MCMV-infection (Fig. 
6C, blood, liver, and ovaries not shown). The percentage of CD8^ T cells staining with 
pp89-tetramer is plotted over time. Each line represents the mean of 3-4 mice per 
experimental group. Error bars indicate the SD within experimental groups.
Figure 7; Efficient induction o f specific CD8^ T cells after infection with recombinant 
MCMV:
7A: Westem-blot analysis of expression of recombinant proteins firom viruses in vitro. 
MEF were infected with wild type (wt) MCMV, with MCMV-NP (NP), with MCMV- 
GP (GP) or, as a negative control, with a mutant MCMV lacking expression of IE2 
(Aie2). To make IE2 expression detectable, protein transcription and translation was 
synchronized by treatment of cells with Cycloheximide for the first 3 hours of infection 
and with Actinomycin D 4 to 7 hours post infection. Protein expression was detected 7 
hours post infection by a mAb specific for IE2. The appropriate IE2 bands are marked on
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the figure. The NP-IE2 and GP-IE2 fusion proteins show a slightly higher molecular 
weight due to the additional NP and GP epitopes, respectively.
7B: C57BL/6 mice were infected with 2x10^ PFU MCMV-GP (left panel) or MCMV- 
NP (right panel). Ten days after infection, splenocytes were harvested, restimulated for 5 
days in vitro and then tested in a 5h-^^Cr-release assay on target cells pulsed with GP33 
(filled triangles), NP366 (filled squares) or an irrelevant peptide (open circles). Each line 
represents an individual mouse. One out of 4 experiments are shown.
7C: NP-tetramer staining of spleen cells from a mouse infected 10 days previously with 
MCMV-NP. The upper panel shows an ex vivo tetramer staining. For the lower panel, 
splenocytes from the same mouse were restimulated for 7 days in vitro with NP366- 
pulsed naïve spleen cells. Numbers indicate the percentage of NP-specific cells of CDS’*" 
T cells. Panels are gated on live lymphocytes without B-cells. One out of 7 mice are 
shown.
Figure 8: Phenotypic characterization o f NP-specific CD8^ T cells after infection with 
MCMV-NP or influenza:
C57BL/6 mice were infected with 2x10^ PFU MCMV-NP i.v. or with 100 
hemagglutination units (HAU) influenza i.n. Spleen cells were harvested at the indicated 
time points and stained with NP-tetramer (NP-tet), anti-CD8, anti-B220 and with anti- 
CD43^ ®^  ^or anti-CD62L. Panels are gated on live lymphocytes without B-cells (Fig. 8A) 
or on live CD8^ lymphocytes (Fig. 8B & 8C). Numbers indicate the percentage of NP- 
specific cells of CD8^ T cells (Fig. 8A) or the percentage of NP-specific CD8^ T cells 
expressing CD43^ ®^  ^ (Fig. 8B) or CD62L (Fig. 8C). One out of 3 similar experiments are 
shown.
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Figure 9: Increasing protective CD8^ T cell -mediated immunity after infection with 
MCMV-NP:
C57BL/6 mice were infected with 2x10^ PFU MCMV-NP i.v. (filled squares) or with 
100 HAU influenza i.n. (filled inverted triangles) or they were left naïve (open circles) as 
a control. Thereafter, the NP-specific CD8^ T cell response was measured longitudinally 
in the blood (Fig. 9A). The percentage of CD8^ T cells staining with NP-tetramer is 
plotted over time. Each line represents the mean of 4-5 mice per experimental group. 
Error bars indicate the SD within experimental groups.
At indicated time points after infection with influenza (Fig. 9B) or MCMV-NP (Fig. 
9C), mice were challenged with VacNP i.p. and the W -titres were measured in the 
ovaries 4 days later (as in Fig. 6B). Titres are given as logio(PFU VacNP/ovaries). The 
detection limit (det. lim.) and the standard deviation (SD) are indicated. Each line 
represents the mean of 4-5 mice per experimental group. The experiment was repeated 
with comparable results until day 220.
Figure 10: Increasing protective CD8^ T cell -mediated immunity after infection with 
MCMV-GP:
C57BL/6-mice were either infected with 2x10^ PFU MCMV-GP i.v. (filled triangles), 
with 5x10^ PFU VacGP i.v. (open triangles) or immunized with the peptide GP33 and 
CFA s.c. (filled diamonds) or they were left naïve (open circles) as a control. Thereafter, 
the GP-specific CD8^ T cell response was measured longitudinally in the spleen by ICS 
(Fig. 10A). The percentage of CD8^ T cells staining for intracellular IFNy after
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stimulation with GP33-41 is plotted over time. Each line represents the mean of 3-4 
mice per experimental group. Error bars indicate the SD within experimental groups.
At indicated time points after immunization with GP33+CFA (Fig. lOB, upper panel) or 
after infection with MCMV-GP (Fig. lOB, lower panel), mice were challenged with 
VacGP i.p. and the W -titres were measured in the ovaries 4 days later. Titres are given 
as logio(PFU VacGP/ovaries). The detection limit was 1.6 and the SD is indicated. Each 
line represents the mean of 4-5 mice per experimental group.
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8. List of Abbreviations
BAL broncho-alveolar lavage
BM bone marrow
BrDU Bromo-deoxy-uridin
CMV cytomegalovirus
E early
EBV Epstein-Barr Virus
Flu-NP nucleoprotein of influenza
GP glycoprotein
HCMV human cytomegalovirus
HIV human Immunodeficiency
Virus
ICS intracellular cytokine
staining 
IE immediate-early
Influenza Influenza A virus
L late
LCMV lymphocytic chorio­
meningitis virus 
LCMV-GP glycoprotein of LCMV 
LN lymph node
MCMV murine cytomegalovirus
MCMV-GP MCMV recombinant for 
LCMV-GP 
MCMV-NP MCMV recombinant for 
Flu-NP
MEF mouse embryonic
fibroblast 
MHV-68 murine y-Herpesvirus-68
NP nucleoprotein
pep peptide
pp phosphoprotein
tetramer MHC class I tetrameric
complexes 
v p  variable region of T cell
receptor p-chain 
W  Vaccinia virus
Vac89 W  recombinant for pp89
VacGP W  recombinant for
LCMV-GP 
VacNP W  recombinant for
Flu-NP
VZV Varicella Zoster virus
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